1. Introduction {#sec1}
===============

For decades, research efforts in subarachnoid hemorrhage (SAH) have focused on vasospasm and delayed ischemic neurological deficits. However, brain injury at the time of aneurysm rupture is a significant predictor of functional outcome. Indeed, poor admission neurological status (Hunt-Hess or World Federation of Neurological Surgeons Score), which reflects acute brain injury, is a larger contributor to death or severe disability than delayed cerebral ischemia \[[@B1], [@B2]\]. However, the mechanism of early brain injury after aneurysm rupture remains elusive and no current therapies are available.

One possible mechanism of acute injury was described in a small case series of 6 patients with observed recurrent aneurysm rupture either during transcranial Doppler (TCD) or during craniotomy with open skull but intact dura. The investigators report a spike in intracranial pressure (ICP) that developed over 1 minute and then declined over several minutes. This abrupt increase in ICP approached levels near mean arterial pressure and led to a concomitant drop in cerebral blood flow resulting in circulatory arrest, as documented by TCD \[[@B3]\]. This study examined aneurysm rebleeding and does not provide direct evidence that intracranial circulatory arrest occurs with de novo aneurysm rupture. However, inadequate cerebral blood flow is frequently evidenced clinically by the transient loss of consciousness that occurs at SAH ictus. This mechanism of global transient circulatory arrest has been described in animal models of SAH at the time of initial hemorrhage \[[@B4], [@B5]\] and mimics the anoxic/hypoxic ischemic mechanism incurred by cardiac arrest.

In this paper, published and ongoing clinical trials in cardiac arrest are compared to those in aneurysmal SAH to identify overlapping or complementary approaches to treatment as well as new avenues for potential research.

2. Methods {#sec2}
==========

A search of PubMed was conducted in 11/2012 to identify randomized, controlled trials of aneurysmal SAH and cardiac arrest. Only human studies of adults (≥18 years of age), which tested an intervention published in English between 1980 and 2012, were included. Only trials examining mortality or neurologic outcome as a primary or secondary endpoint were reviewed. Only trials specific to SAH (not trials that included other neurocritical diagnoses or brain injury diagnoses) were included. Cardiac arrest trials included both out-of-hospital and in-hospital arrest and all arrest rhythms were included. Post hoc analyses of preexisting trials were not reviewed. If phase III results of a trial were available, earlier phases of the same trial were not included in analysis unless the patient population or methodology differed substantially.

A PubMed search of the term "subarachnoid hemorrhage" and "neurologic outcome" with the limits of human, age \> 18, English and randomized, controlled trial yielded 23 results. A PubMed search of the term "subarachnoid hemorrhage" and "mortality" with the limits of human, age \> 18, English and randomized, controlled trial yielded 78 results. An additional review of articles identified by a broader search of "subarachnoid hemorrhage" with the limits of human, age \> 18, English and randomized, controlled trial yielded 244 results. Review of these studies yielded 57 aneurysmal SAH trials that met inclusion criteria and were analyzed. A pubmed search of the terms "cardiac arrest" and "neurologic outcome" with the limits of human, English, age \> 18 and randomized, controlled trial yielded 21 results. A PubMed search of the terms "cardiac arrest" and "mortality" with the limits of human, English, age \> 18 and randomized, controlled trial yielded 197 results. Review of these studies yielded 46 cardiac arrest trials that met inclusion criteria and were analyzed.

Clinicaltrials.gov was searched for ongoing interventional trials in cardiac arrest and aneurysmal subarachnoid hemorrhage. Only ongoing studies that were open and recruiting or preparing to recruit were included. Terminated studies were excluded from review. A search of ongoing studies on clinicaltrials.gov for the term "subarachnoid hemorrhage", limited to interventional studies of adults ≥18 years old, produced 86 results and a search for the term "cardiac arrest" limited to interventional studies of adults with neurologic outcomes produced 46 results. Of these, 25 ongoing SAH trials and 14 cardiac arrest trials met the criteria for review.

3. Results {#sec3}
==========

3.1. Trials Analyzed {#sec3.1}
--------------------

A total of 142 trials (82 SAH, 60 cardiac arrest) met review criteria. Of these, 103 were published in peer-reviewed journals and 39 were ongoing studies. Fifty-seven published randomized, controlled studies were identified in the SAH population and 46 in the cardiac arrest population. These studies are reviewed in detail in Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}. Additionally, 25 ongoing SAH trials and 14 ongoing cardiac trials were reviewed (Tables [3](#tab3){ref-type="table"} and [4](#tab4){ref-type="table"}).

3.2. Interventions Studied {#sec3.2}
--------------------------

The main hypothetical mechanisms of intervention tested in published SAH trials were related to treating or preventing delayed cerebral ischemia (*N* = 40, 70%), preventing aneurysm rebleeding (*N* = 5, 9%), improving aneurysm repair technique (*N* = 5, 9%), improving fluid balance (*N* = 2, 4%), and others (*N* = 3, 5%). Among ongoing SAH trials, mechanisms of study include treating or preventing delayed cerebral ischemia (*N* = 19, 76%), limiting rebleeding (*N* = 1, 4%), improving aneurysm repair (*N* = 1, 4%), seizure control (*N* = 2, 8%), and other (*N* = 2, 8%). There are no published or ongoing SAH clinical trials that focus on treating acute brain injury after aneurysm rupture.

Conversely, the main mechanisms of intervention studied in *published*cardiac arrest trials focused on acute intervention to treat and limit early brain injury. All 46 (100%) published cardiac arrest trials focused on the acute time frame (first few hours) after cardiac arrest. Interventions studied included decreasing cerebral metabolic demand with hypothermia or barbiturate (*N* = 6, 13%), high-quality chest compressions or pressor use to return cerebral blood flow (*N* = 16, 35%), electrolyte/metabolic optimization with calcium, magnesium, sodium bicarbonate or insulin administration (*N* = 12, 26%), neuroprotective drugs including calcium channel blockers (*N* = 5, 11%), thrombolysis to treat the underlying cause of cardiac arrest (*N* = 2, 4%) and other (*N* = 5, 11%). Among *ongoing* cardiac arrest trials, mechanisms of study include decreasing cerebral metabolic demand with hypothermia (*N* = 9, 64%), high-quality chest compressions to return cerebral blood flow (*N* = 2, 14%) electrolyte/metabolic optimization with magnesium (*N* = 1, 7%), neuroprotective drugs (*N* = 1, 7%), and monitoring cerebral oxygenation (*N* = 1, 7%). A detailed list of interventions from published and ongoing studies in both the SAH and cardiac arrest population are listed in [Table 5](#tab5){ref-type="table"}.

3.3. Outcome Measures {#sec3.3}
---------------------

The most common neurological outcomes assessed in the SAH trials were delayed cerebral ischemia (*N* = 24, 42%), functional outcome (Glasgow outcome scale, modified Rankin scale or functional outcome scale, *N* = 24, 42%), angiographic or transcranial Doppler vasospasm (*N* = 6, 11%), and death (*N* = 4, 7%). Among cardiac arrest trials, the most often assessed neurological outcomes were the Pittsburgh cerebral performance score (*N* = 18, 40%), Glasgow outcome score or modified Rankin Score (*N* = 4, 9%), Glasgow coma score (*N* = 4, 9%), awakening and command following (*N* = 3, 7%), cognitive or neuropsychological testing (*N* = 1, 2%), "disability" (*N* = 1, 2%), death (*N* = 13, 30%), discharge disposition (*N* = 1, 2%) and others (*N* = 1, 2%).

3.4. Trial Results {#sec3.4}
------------------

Of the clinical trials reviewed for SAH, 30% (17/57) showed that the intervention tested had a statistically significant impact on neurological outcome or mortality. These include studies of nimodipine \[[@B9]--[@B10], [@B8], [@B6]\], phase II data for nicardipine implants during aneurysm clipping \[[@B11]\], the neuroprotectants edavarone \[[@B12]\] and nizofenone \[[@B13]\], pravastatin \[[@B14]\], early aneurysm surgery \[[@B15]\], endovascular coiling \[[@B17]--[@B16]\], cilostazol \[[@B19]\], methylprednisolone \[[@B20]\], erythropoietin \[[@B21]\], and fasudil \[[@B23], [@B22]\]. Similarly, 30% (17/57) of studies showed a positive impact on delayed cerebral ischemia, infarction, angiographic or TCD vasospasm, though there was incomplete overlap with the above studies that showed outcome benefit. Eight studies found both a significant improvement in delayed cerebral ischemia/vasospasm/infarction and outcome including studies of nimodipine \[[@B9], [@B10], [@B8]\], nicardipine implants in the basal cistern \[[@B11]\], edavarone \[[@B12]\], pravastatin \[[@B14]\], fasudil \[[@B23]\], and erythropoietin \[[@B21]\]. Nine studies found a benefit for decreasing delayed cerebral ischemia/vasospasm/infarction but no neurologic outcome benefit including studies of IV nicardipine \[[@B24], [@B25]\], eicosapentaenoic acid (omega-3 fatty acid) \[[@B26]\], the neuroprotectant NA-1 \[[@B27]\], simvastatin \[[@B28]\], tirilazad \[[@B29]\], intracisternal rTPA \[[@B30], [@B31]\], and clazosentan \[[@B32], [@B33]\]. Three studies found improved neurologic outcome despite an insignificant effect on delayed cerebral ischemia/vasospasm/infarction including studies of cilostazol \[[@B19]\], methylprednisolone \[[@B20]\], and fasudil \[[@B22]\].

Among the cardiac arrest trials, 13% (6/46) demonstrated neurologic or mortality benefit. Improved mortality rates were demonstrated with mild therapeutic hypothermia \[[@B40]\], coenzyme Q10 \[[@B36]\], vasopressin plus epinephrine plus methylprednisolone \[[@B37]\], active compression-decompression CPR \[[@B38]\], and hemofiltration \[[@B39]\]. Improved neurological outcome was demonstrated with early mild therapeutic hypothermia for ventricular fibrillation and pulseless ventricular tachycardia arrests \[[@B41], [@B40]\], and one study of active compression-decompression CPR \[[@B38]\], though a larger study of active compression-decompression was negative \[[@B42]\].

3.5. Trial Overlap {#sec3.5}
------------------

Though nimodipine has demonstrated mortality and functional outcome benefit in SAH \[[@B9]--[@B10], [@B8], [@B6]\], it has shown no benefit in cardiac arrest trials \[[@B43], [@B44], [@B45]\]. Similarly, intracisternal thrombolysis showed some benefit in reducing delayed cerebral ischemia and infarction after SAH \[[@B30], [@B31]\], but intravenous tenecteplase showed no long-term benefit and, in fact, increased intracranial hemorrhage after cardiac arrest \[[@B47], [@B46]\]. Neither magnesium \[[@B54], [@B49], [@B53]--[@B52]\] nor intensive insulin \[[@B55], [@B56]\] has proven beneficial after SAH or cardiac arrest. Though hypothermia \[[@B41], [@B40]\] has been the single most effective treatment for cardiac arrest (the number needed to treat to prevent one death is 7 and the number needed to treat to produce favorable neurological outcome is 6), it has not proven useful in the context of aneurysm surgery after SAH \[[@B57]\]. There is little mechanistic overlap in ongoing randomized, controlled trials of SAH and cardiac arrest patients.

4. Discussion {#sec4}
=============

In this paper, a direct comparison is made between randomized, controlled clinical trials that evaluate mortality or neurologic outcome after SAH and cardiac arrest. Though 28% of SAH studies showed some neurologic outcome benefit in the intervention group, only nimodipine \[[@B9]--[@B10], [@B8], [@B6]\], fasudil \[[@B23], [@B22]\], and endovascular coiling \[[@B17]--[@B16]\] have been found to consistently improve outcome in multiple, multi-center randomized controlled trials. Smaller studies \[[@B8], [@B19], [@B22]\], single center \[[@B12], [@B20]\], or phase II safety and feasibility studies \[[@B11], [@B14], [@B21]\] have shown outcome benefit, but still require larger efficacy trials before integration into standard practice. Among cardiac arrest trials, only mild therapeutic hypothermia has been shown to improve both mortality and neurologic outcome \[[@B41], [@B40]\]. Little overlap in trial results or mechanisms of study was identified in these different patient populations.

Methodological differences in the timing, duration, neurological severity, and outcomes studied may explain some of the differences in trial results between SAH and cardiac arrest populations. First, the timing of intervention for SAH and cardiac arrest trials is quite different. With the exception of aneurysm repair and aneurysm rebleeding trials (some of which were carried out in the era of delayed surgical treatment), the vast majority of SAH trials focus on the delayed cerebral ischemia period. Conversely, all cardiac arrest trials are directed at intervening against early brain injury. The difference in time frames studied may explain, in part, the variable results for mild therapeutic hypothermia in each population. Unlike the cardiac arrest trials, which applied hypothermia either prior to ED arrival \[[@B41]\] or within a median of 105 minutes from return of spontaneous circulation (ROSC) \[[@B40]\] for a duration of 12--24 hours, hypothermia was applied in the IHAST trial at a median of two days from SAH onset and only for a brief time (median 5-6 hours) \[[@B57]\]. Second, patient selection may result in variable trial results for hypothermia. For example, hypothermia for cardiac arrest was used for comatose survivors, while relatively neurologically intact patients (WFNS I--III) were studied in the IHAST trial. Finally, outcome measures differ in the cardiac arrest and SAH literature. Many cardiac trials measure 30-day or discharge mortality or neurologic outcome, while SAH trials measure outcomes from 3 months to 1 year. Though the majority of cardiac arrest trials measure neurologic outcome using the Pittsburgh cerebral performance scale, while SAH trials utilize the Glasgow outcome scale or modified Rankin scale, all of these scales are very similar and provide gross estimates of disability. Despite the aforementioned methodological differences, certain interventions, such as magnesium and intensive insulin, have not proven effective in either population.

Another reason for variable outcome in clinical trials may be due to pathophysiological differences in SAH and cardiac arrest. Though early brain injury in SAH may mechanistically mirror the cascade of injury occurring after cardiac arrest, SAH differs from cardiac arrest in that it is not a monophasic disease. Break down of blood products initiates a distinctive series of delayed clinical events that characteristically can lead to ischemia or infarction between SAH days 3--14. The fact that nimodipine has been so successful in SAH trials, but shown no effect at similar doses in cardiac arrest trials suggests it is acting on a distinct pathway. Indeed, the absolute risk reduction for poor outcome after SAH in a meta-analysis of 16 trials of nimodipine is 5.3% with a number needed to treat for benefit of 19 \[[@B58]\]. No such signal for benefit was seen in cardiac arrest trials \[[@B43], [@B44], [@B45]\]. The mechanism of beneficial effect of nimodipine in SAH has been widely debated and may be related to its effect on fibrinolysis \[[@B59]\], spreading cortical depression \[[@B60]\], or excitotoxicity. Though nimodipine improves ischemic neurological deficits by clinical criteria and CT-documented infarction (with a pooled relative risks of 0.66 (95% CI 0.59--0.75) and 0.78 (95% CI 0.70--0.87), resp.) \[[@B58]\], it has little effect on angiographic vasospasm or cerebral blood flow \[[@B9], [@B7]\]. The corollary to this observation is that interventions that improve angiographic vasospasm, such as clazosentan, do not necessarily improve cerebral infarction or outcome. \[[@B32], [@B33], [@B61], [@B62]\]. While angiographic vasospasm seems to be related to infarction \[[@B63]\], other mechanisms may play a role in neurological deficits, cerebral infarction, and outcome. Such pathophysiological differences may make extrapolation of results from cardiac arrest trials to an SAH population problematic. Indeed, delayed cerebral ischemia (DCI) may blunt the positive effect of hypothermia on early brain injury. Further animal research may better identify mechanistic differences of early brain injury in cardiac arrest and SAH.

Despite a second wave of neurological injury in SAH, poor-grade (Hunt Hess 4-5) SAH patients, who are at higher risk for secondary neurological injury, still have comparable, if not better, outcomes compared to cardiac arrest patients who are not cooled. Among Hunt-Hess grade 4-5 patients, the 12-month mortality rate with aggressive treatment is 43%, while 40% had no or slight-moderate disability (mRS 0--3) \[[@B64]\]. By comparison, the 6-month death rate in the control (nonhypothermia) group of the HACA trial was 55%, while good neurologic outcome (defined as Pittsburgh cerebral performance scale 1-2; good outcome or moderate disability) occurred in 26--39% \[[@B41], [@B40]\]. We have additionally shown that DCI does not predict mortality after SAH with aggressive vasospasm treatment, while early brain injury (measured by Hunt-Hess grade) does \[[@B1]\]. Thus, despite secondary neurologic insults and delayed cerebral ischemia risk, poor-grade SAH patients do at least as well as normothermic cardiac arrest patients, who may face risks to survival and functional outcome related to the underlying cause of the cardiac arrest. Also, the median age of cardiac arrest patients tends to be older than SAH patients, which may also explain why even the sickest SAH patients have relatively good outcomes by comparison. If nihilism can be overcome in the management of poor-grade SAH patients, the early application of mild therapeutic hypothermia may improve outcomes further.

There are some limitations to this review that should be mentioned. A medical librarian was not used and only MEDLINE/PubMed and clinicaltrials.gov were used to identify literature for review. An Embase search was not performed. Additionally, an exhaustive search for all neurologic outcome based RCTs was not performed, rather only English studies in humans were included.

In conclusion, while the mechanisms of early brain injury after SAH and cardiac arrest may be similar, the preponderance of SAH clinical trials do not focus on interventions addressing early brain injury. Clinical trials in SAH assessing interventions that have proven successful in the cardiac arrest literature, such as early mild therapeutic hypothermia, are warranted.
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  Cerebral Arterial Spasm---a controlled Trial of Nimodipine in Patients with Subarachnoid Hemorrhage                                                                                                                                                                                 Randomized, placebo-controlled, double-blind, multicenter prospective study of Hunt Hess grade I-II SAH patients                                                Nimodipine 0.7 mg/kg PO bolus, then 0.35 mg/kg q 4 × 21 days. Starting within 96 h of SAH (*N* = 58)                                                         Placebo (*N* = 63)                                                                                         Primary outcome: neurological deficit from arterial spasm and severity of neurologic deficit at 21 days                                                                                                                                                                                      Nimodipine significantly reduced death or severe deficits from spasm at 21 days (2% versus 13% with placebo, *P* = 0.03)                                                                                                                                                                                                                                                                                                                                                Allen et al., NEJM 1983 \[[@B65]\]

  Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial                                                                                                                                                                Randomized, multicenter, double-blind, placebo-controlled trial                                                                                                 Nimodipine 90 mg PO q 4 h × 21 d (*N* = 91)                                                                                                                  Placebo (*N* = 97)                                                                                         Primary outcome: 3-month GOS\                                                                                                                                                                                                                                                                Better 3-month GOS in treatment group (29% versus 9% of treatment group, *P* \< 0.001). Significantly less delayed cerebral ischemia in treatment group, no difference in angiographic vasospasm                                                                                                                                                                                                                                                                        Petruk et al., J Neurosurg 1988 \[[@B9]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Secondary outcomes: delayed ischemic deficits, angiographic vasospasm                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Controlled study of nimodipine in aneurysm patients treated early after subarachnoid hemorrhage                                                                                                                                                                                     Randomized, double-blind, placebo-controlled trial of all Hunt-Hess grades within 96 hours of SAH                                                               Nimodipine 60 mg q 4 h PO × 21 days + Nimodipine 200 mcg IV intraoperatively into basal cistern (*N* = 38)                                                   Placebo (*N* = 37)                                                                                         Primary outcome: mortality, cerebral blood flow measured by Xenon CT\                                                                                                                                                                                                                        Mortality was lower in the nimodipine group (4% versus 24% with placebo, *P* \< 0.05). Nimodipine did not significantly increase cerebral blood flow                                                                                                                                                                                                                                                                                                                    Mee et al., Neurosurgery 1988 \[[@B7]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Secondary outcomes: 3-month intellectual or neurological deficit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid hemorrhage: British aneurysm nimodipine trial                                                                                                                                                       Randomized, double-blind, placebo-controlled, multicenter trial within 96 h of SAH                                                                              Nimodipine 60 mg q 4 PO × 21 d (*N* = 276)                                                                                                                   Placebo (*N* = 278)                                                                                        Primary outcome: 3-month cerebral infarction Secondary outcome: 3-month GOS                                                                                                                                                                                                                  Significantly less cerebral infarction in the nimodipine group (22% compared to 33% in placebo, *P* = 0.014). Poor GOS outcomes significantly reduced in nimodipine group at 3-months                                                                                                                                                                                                                                                                                   Pickard et al., BMJ 1989 \[[@B10]\]

  Early aneurysm surgery and preventive Therapy with intravenously administered nimodipine: A multicenter, double-blind, dose-comparison study                                                                                                                                        Randomized, double-blind, dose-comparison, multicenter study                                                                                                    Nimodipine 2 mg/h IV for 9--15 days\                                                                                                                         Nimodipine 3 mg/h IV for 9--15 days\                                                                       Primary outcome: delayed neurological deficits, adverse drug reactions                                                                                                                                                                                                                       No difference in delayed neurological deficits between the two groups                                                                                                                                                                                                                                                                                                                                                                                                   Gilsbach et al., Neurosurgery 1990 \[[@B66]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N* = 101)                                                                                                                                                  (*N* = 103)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Long-term effects of nimodipine on cerebral infarcts and outcome after aneurysmal subarachnoid hemorrhage and surgery                                                                                                                                                               Randomized, double-blind, placebo-controlled of Hunt-Hess I--III SAH patients                                                                                   Nimodipine IV 0.5 mcg/kg/min × 7--10 days followed by 60 mg q 4 h PO × 21 days total\                                                                        Placebo (*N* = 109)                                                                                        Primary outcome: delayed ischemic deterioration and CT infarcts\                                                                                                                                                                                                                             Significantly fewer deaths caused by delayed cerebral ischemia in nimodipine group (*P* = 0.01) and fewer cerebral infarcts on CT (*P* = 0.05). No differences in 1--3 year GOS or CT scan                                                                                                                                                                                                                                                                              Ohman et al., J Neurosurg 1991 \[[@B8]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N* = 104)                                                                                                                                                                                                                                                             Secondary outcomes: GOS at 1--3 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  A randomized outcome study of enteral versus intravenous nimodipine in 171 patients after acute aneurysmal subarachnoid hemorrhage                                                                                                                                                  Randomized, single-center study                                                                                                                                 Nimodipine 2 mg/h IV × 10 days then changed to PO × 6 d\                                                                                                     Nimodipine 60 mg PO q 4 × 16 days \                                                                        Primary outcome: delayed ischemic neurological deficit\                                                                                                                                                                                                                                      No difference in delayed ischemic neurological deficits (20% in enteral versus 16% in IV group, *P* = 0.61), no difference in 12-month clinical outcomes                                                                                                                                                                                                                                                                                                                Soppi et al., World Neurosurgery 2012 \[[@B67]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N* = 87)                                                                                                                                                   (*N* = 84)                                                                                                 Secondary outcomes: 12 month GOS, mRS, Karnofsky, MRI infarcts, HRQoL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Calcium channel blockers---nicardipine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. A report of the cooperative aneurysm study                                                                                                                                Randomized, double-blind, placebo-controlled, multicenter study                                                                                                 Nicardipine IV 0.15 mg/kg/h (*N* = 449)                                                                                                                      Placebo (*N* = 457)                                                                                        Primary outcome: 3-month GOS\                                                                                                                                                                                                                                                                No difference in 3-month GOS. Less symptomatic vasospasm in treatment group (32% versus 46% in placebo group, *P \<*0.001) and less angiographic vasospasm in treatment group (33% versus 51% of placebo, *P \<*0.01) and less TCD vasospasm (23% versus 49% of placebo, *P \<*0.001)                                                                                                                                                                                   Haley et al., J Neurosurg 1993 \[[@B24], [@B25]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Secondary outcomes: angiographic vasospasm, TCD vasospasm, mortality, disability from vasospasm, symptomatic vasospasm, CT infarction, NIHSS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  A randomized trial of two doses of nicardipine in aneurysmal subarachnoid hemorrhage. A report of the cooperative aneurysm study                                                                                                                                                    Randomized, double-blind, multicenter study                                                                                                                     Nicardipine IV 0.15 mg/kg/h × 14 days\                                                                                                                       Nicardipine IV 0.075 mg/kg/h × 14 days\                                                                    Primary outcome: symptomatic vasospasm, adverse drug events Secondary outcomes: 3-month GOS and NIHSS, mortality, disability due to vasospasm, CT infarction                                                                                                                                 No difference in symptomatic vasospasm or 3-month outcome. More adverse effects in high-dose nicardipine group                                                                                                                                                                                                                                                                                                                                                          Haley et al., J Neurosurg 1994 \[[@B68]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*184)                                                                                                                                                   (*N =*181)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Effect of nicardipine prolonged-release implants on cerebral vasospasm and clinical outcome after severe aneurysmal subarachnoid hemorrhage. A prospective, randomized, double-blind phase IIa Study                                                                                Randomized, prospective double-blind phase IIa study in clipped SAH patients                                                                                    Nicardipine prolonged-release implants (10 × 4 mg prolonged release rod shaped polymers) placed in basal cisterns\                                           Control-basal cisterns opened and washed out (*N =*16)                                                     Primary outcome: angiographic vasospasm Secondary outcome: delayed ischemic lesion on HCT, 1-year mRS and NIHSS                                                                                                                                                                              Angiographic vasospasm significantly reduced in treatment group (7% versus 73% in controls, *P \<*0.05). No significant difference in CT infarct. Decreased mortality in treatment group (6% versus 38% in control group, *P =*0.042) and better 1-year mRS and NIHSS (*P =*0.0001)                                                                                                                                                                                     Barth et al., Stroke 2007 \[[@B11]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*16)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Antifibrinolytics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: A consecutive controlled clinical trial                                                                                                                                                                Randomized, placebo-controlled, study                                                                                                                           Tranexamic acid 1 g q 4 h IV × 1 week then 1 g q 6 h IV × 1 week then 1.5 g q 6 h PO × 1 week\                                                               Placebo\                                                                                                   Primary outcome: recurrent hemorrhage diagnosed by LP, HCT, echoencephalogram or autopsy.\                                                                                                                                                                                                   Tranexamic acid protected against rebleeding during the first 2 weeks of treatment but also resulted in cerebral ischemic complications                                                                                                                                                                                                                                                                                                                                 Fodstad et al., Neurosurgery 1981 \[[@B69]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*30)                                                                                                                                                    (*N =*29)                                                                                                  Secondary outcome: angiographic vasospasm, delayed cerebral ischemia, death                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Comparative clinical trial of epsilon amino-caproic acid and tranexamic acid in the prevention of early recurrence of subarachnoid hemorrhage                                                                                                                                       Randomized trial                                                                                                                                                Epsilon amino-caproic acid 6 g q 6 h IV continued until surgery or discharge\                                                                                Tranexamic acid 1 g q 6 h IV continued until surgery or discharge\                                         Primary outcome: recurrent hemorrhage diagnosed clinically by HCT, LP, or autopsy\                                                                                                                                                                                                           Rebleeding occurred in 8% of aminocaproic-acid-treated patients and 10% of tranexamic acid treated patients. Delayed ischemic deficits occurred in 7% of aminocaproic acid patients and 5% of tranexamic acid patients. Mortality was 11% in each group. *P =*NS for all outcomes                                                                                                                                                                                       Chowdhary and Sayed, JNNP 1981 \[[@B70]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*90)                                                                                                                                                    (*N =*61)                                                                                                  Secondary outcome: delayed ischemic deficit diagnosed by clinical deterioration, angiographic vasospasm, and infarct on HCT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Antifibrinolytic treatment in subarachnoid hemorrhage                                                                                                                                                                                                                               Randomized, double-blind, placebo-controlled, multicenter study                                                                                                 Tranexamic acid 1 g q 4 h IV × 1 week then 1 g q 6 h IV × 3 weeks\                                                                                           Placebo\                                                                                                   Primary outcome: 3-month GOS\                                                                                                                                                                                                                                                                Rebleeding reduced from 24% in control group to 9% in treatment group (*P \<*0.001), but with concurrent increase in ischemic complications (24% in treatment group versus 15% in placebo, *P \<*0.01). No difference in 3 month GOS                                                                                                                                                                                                                                    Vermeulen et al., NEJM 1984 \[[@B71]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N* = 241)                                                                                                                                                  (*N =*238)                                                                                                 Secondary outcome: neurological deterioration, rebleeding, infarction, hydrocephalus, edema, epilepsy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Antifibrinolytic treatment in subarachnoid hemorrhage: a randomized placebo-controlled trial (STAR)                                                                                                                                                                                 Prospective, double-blind, placebo-controlled, multicenter, randomized trial within 96 hours of SAH onset in whom aneurysm repair was delayed beyond 48 hours   Tranexamic acid 1 g IV q 4 h × 1 week then 1.5 g PO q 6 h × 2 weeks\                                                                                         Placebo\                                                                                                   Primary outcome: 3-month GOS\                                                                                                                                                                                                                                                                No difference in 3-month GOS. Significant decrease in rebleeding from 33% in placebo group to 19% in treatment group. No difference in delayed cerebral ischemia, hydrocephalus, or postoperative ischemia                                                                                                                                                                                                                                                              Roos, Neurology 2000 \[[@B72]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*229)                                                                                                                                                   (*N =*233)                                                                                                 Secondary outcomes: rebleeding, delayed cerebral ischemia, hydrocephalus, postoperative ischemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study                                                                                                                      Randomized, placebo-controlled trial                                                                                                                            Tranexamic acid 1 g IV bolus, then 1 g IV q 6 hours until aneurysm repair or 72 hours post ictus.\                                                           Placebo\                                                                                                   Primary outcome: Rebleeding by HCT\                                                                                                                                                                                                                                                          Treatment group had reduced rebleeding rate of 2.4% compared to 10.8% in the placebo group (*P \<*0.01). More favorable outcome in the treatment group (74.8% compared to 70.5% in the control group, *P =*NS). No increased risk of ischemia                                                                                                                                                                                                                           Hillman et al., J Neurosurg 2002 \[[@B73]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*254)                                                                                                                                                   (*N =*251)                                                                                                 Secondary outcome: 6 -month GOS, clinical vasospasm/delayed ischemic neurological deficit, TCD spasm                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Neuroprotectives drugs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  A double-blind clinical evaluation of the effect of nizofenone on delayed ischemic neurological deficits following aneurysmal rupture                                                                                                                                               Randomized, placebo controlled trail                                                                                                                            Nizofenone for 5--10 days\                                                                                                                                   Placebo\                                                                                                   Primary outcome: delayed ischemic neurological deficits with angiographically confirmed vasospasm.\                                                                                                                                                                                          No difference in delayed ischemic events between treatment groups. Among patients with vasospasm, those who received nizofenone had better one-month functional outcomes (*P \<*0.05)                                                                                                                                                                                                                                                                                   Saito et al., Neurol Res 1983 \[[@B74]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*42)                                                                                                                                                    (*N =*48)                                                                                                  Secondary outcomes: one-month disability index, motor, and speech function                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Nizofenone administration in the acute stage following subarachnoid hemorrhage. Results of a multicenter controlled double-blind clinical study                                                                                                                                     Randomized, double-blind, placebo-controlled, multicenter study of Hunt Hess grade I--IV                                                                        Nizofenone 5 mg × 2 weeks\                                                                                                                                   Placebo\                                                                                                   Primary outcome: neurological exam at 1-month and discharge                                                                                                                                                                                                                                  Significantly improved one-month or discharge functional outcome in treatment group compared to placebo (*P \<*0.05). No difference in mortality                                                                                                                                                                                                                                                                                                                        Ohta et al., J Neurosurg 1986 \[[@B13]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*102)                                                                                                                                                   (*N =*106)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Effect of a free radical scavenger, edaravone, in the treatment of patients with aneurysmal subarachnoid hemorrhage                                                                                                                                                                 Randomized, controlled, single-center study                                                                                                                     Edaravone 30 mg IV BID × 14 days\                                                                                                                            Control (usual treatment)\                                                                                 Primary outcome: delayed ischemic neurological deficits\                                                                                                                                                                                                                                     No difference in delayed ischemic neurological deficits between treatment and control groups. Less cerebral infarction in treatment group (0% versus 66%, *P =*0.028). Poor outcome caused by vasospasm 0% in treatment group and 71% in control group (*P =*0.046)                                                                                                                                                                                                     Munakata et al., Neurosurgery 2009 \[[@B12]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*49)                                                                                                                                                    (*N =*42)                                                                                                  Secondary outcomes: cerebral infarction due to vasospasm, 3-month GOS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study (EVAS)                                                                                                                                                                                                                       Randomized, controlled, open label, multicenter, efficacy study of surgically clipped SAH patients                                                              Eicosapentaenoic acid (omega 3 fatty acid) 900 mg TID × 30 days\                                                                                             Control (usual treatment)\                                                                                 Primary outcome: symptomatic vasospasm or infarct on HCT\                                                                                                                                                                                                                                    Symptomatic vasospasm occurred significantly less in the treatment group (15% versus 30% in controls, *P =*0.022) as did infarction from vasospasm (7% versus 21% in controls, *P =*0.012)                                                                                                                                                                                                                                                                              Yoneda et al., World Neurosurg 2012 \[[@B26]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*81)                                                                                                                                                    (*N =*81)                                                                                                  Secondary outcome: 1-month GOS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomized, double-blind, placebo-controlled trial                                                                                                            Randomized, double-blind, placebo-controlled study of ruptured (WFNS 1--3) and unruptured aneurysms undergoing endovascular repair                              NA-1 2.6 mg/kg infusion over 10 minutes\                                                                                                                     Placebo\                                                                                                   Primary outcome: safety, number and volume of ischemic strokes on MRI DWI and FLAIR 12--96 hours after infusion Secondary outcome: 30-day mRS, NIHSS, neurocognitive outcome                                                                                                                 No difference in MRI lesion volume, but fewer ischemic lesions in NA-1 group compared to placebo (*P =*0.012). In the SAH subgroup (20% of cohort) their MRI number and ischemic volume was significantly less in the treatment group. No difference in 30 day NIHSS or mRS between groups                                                                                                                                                                              Hill et al., Lancet Neurol 2012 \[[@B27]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*92)                                                                                                                                                    (*N =*93)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Statins                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Simvastatin reduces vasospasm After aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial                                                                                                                                                                Randomized, placebo-controlled pilot trial                                                                                                                      Simvastatin 80 mg qd for 14 days\                                                                                                                            Placebo\                                                                                                   Primary outcome: delayed ischemic neurological deficit confirmed by TCD or angiography.\                                                                                                                                                                                                     Vasospasm occurred in 26% of treatment group compared to 60% of placebo group (*P \<*0.05). No differences in transaminitis or myositis. VWF and S100 were significantly lower in the treatment group (*P \<*0.05)                                                                                                                                                                                                                                                      Lynch et al., Stroke 2005 \[[@B28]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*19)                                                                                                                                                    (*N =*20)                                                                                                  Secondary outcomes: liver transaminases, CK, von Willebrand factor, S100                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed Ischemic deficits after aneurysmal subarachnoid hemorrhage. A phase II randomized placebo-controlled trial                                                                           Randomized placebo-controlled, phase II Trial                                                                                                                   Pravastatin 40 mg PO qd × 14 d\                                                                                                                              Placebo\                                                                                                   Primary outcome: incidence, severity, and duration of vasospasm on TCD, duration of impaired autoregulation measured by transient hyperemic response on TCD\                                                                                                                                 TCD vasospasm and severe vasospasm were reduced in the treatment group (*P =*0.006 and *P =*0.044, resp.). Duration of impaired autoregulation shortened in treatment group (*P \<*0.01). Vasospasm-related delayed ischemic deficits was reduced (*P \<*0.001) and mortality was reduced (*P =*0.037)                                                                                                                                                                  Tseng et al., Stroke 2005 \[[@B14]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*40)                                                                                                                                                    (*N =*40)                                                                                                  Secondary outcome: vasospasm-related delayed ischemic deficits, disability at discharge                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  A randomized, double-blind, placebo-controlled pilot study of simvastatin in aneurysmal subarachnoid hemorrhage                                                                                                                                                                     Randomized, double-blind, placebo-controlled pilot study                                                                                                        Simvastatin 80 mg qd in statin naïve Fisher 3 SAH until discharge or 21 days\                                                                                Placebo\                                                                                                   Primary outcome: death and drug morbidity (elevated CK, transaminases)\                                                                                                                                                                                                                      Mortality in 0% treatment group and 15% placebo group. Angiographically confirmed vasospasm in 26% treatment group and 25% placebo group. Vasospasm infarcts in 11% treatment group and 25% placebo group. All differences *P =*NS                                                                                                                                                                                                                                      Chou et al., Stroke 2008 \[[@B75]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*19)                                                                                                                                                    (*N =*20)                                                                                                  Secondary outcomes: TCD, angiographic or clinical vasospasm, vasospasm-related infarcts, clinical outcomes at discharge, cardiac, and infectious morbidities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Biological effects of simvastatin in patients with aneurysmal subarachnoid hemorrhage: a double-blind, placebo-controlled randomized trial                                                                                                                                          Double-blind, placebo-controlled randomized trial                                                                                                               Simvastatin 80 mg PO × 15 days\                                                                                                                              Placebo\                                                                                                   Primary outcome: effect of simvastatin on laboratory parameters of endothelial function, fibrinolysis, coagulation, inflammation and cholesterol\                                                                                                                                            Simvastatin group had significantly lower total cholesterol and LDL, but no differences in coagulation, fibrinolysis, endothelium function, or inflammation. No differences in TCD vasospasm, clinical DCI, or poor outcome                                                                                                                                                                                                                                             Vergouwen et al., J Cereb Blood Flow Metab 2009 \[[@B76]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*16)                                                                                                                                                    (*N =*16)                                                                                                  Secondary outcomes: TCD vasospasm, clinical signs of DCI, 3- and 6-month GOS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Aneurysm repair                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Timing of operation for ruptured supratentorial aneurysms: a prospective randomized study                                                                                                                                                                                           Randomized, prospective study of Hunt Hess grade I--III SAH patients                                                                                            Acute surgery (day 0--3 after SAH)\                                                                                                                          Intermediate surgery (day 4--7 after SAH)\                                                                 Primary outcome: 3-month dead, dependent or independent.\                                                                                                                                                                                                                                    Acute surgery patients were more often independent at 3-months (92% versus 79% in intermediate timing and 80% in the late timing group, *P \<*0.01). Mortality was 6% in the early surgery group versus 13% in the late surgery group (*P =*NS)                                                                                                                                                                                                                         Ohman and Heiskanen, J Neurosurg 1989 \[[@B15]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*71)                                                                                                                                                    (*N =*70)\                                                                                                 Secondary outcomes: Neurological deficit from direct effect of initial bleed, complication of surgery, confirmed rebleeding, delayed ischemic deterioration, hydrocephalus, extracranial complications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Late surgery (day 8 or later after SAH)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   (*N =*70)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomized trial                                                                                                    Randomized, unblinded trial of SAH patients with an aneurysm judged technically suitable for either clipping or coiling and clinical equipoise                  Surgical clipping\                                                                                                                                           Endovascular treatment by detachable platinum coils\                                                       Primary outcome: 1-year mRS 3--6 versus 1-2 Secondary outcomes: rebleeding, quality of life at 1 year (euroQol), frequency of epilepsy, cost effectiveness, neuropsychological outcomes                                                                                                      Dependent or dead at 1 year: 23.7% endovascular versus 30.6% clipping (*P =*0.0019).                                                                                                                                                                                                                                                                                                                                                                                    Molyneux et al., ISAT Collaborative Group, Lancet 2002 \[[@B17]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*1070)                                                                                                                                                  (*N =*1073)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomized comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion   Randomized, unblinded trial of SAH patients with an aneurysm judged technically suitable for either clipping or coiling and clinical equipoise                  Surgical clipping\                                                                                                                                           Endovascular treatment by detachable platinum coils\                                                       Primary outcome: 1-year mRS 3--6 versus 1-2\                                                                                                                                                                                                                                                 Dead or dependent at 1-year: 23.5% of endovascular group versus 30.9% of clipping group. ARR 7.4%. Early survival advantage of coiling maintained up to 7 years (*P =*0.03). Lower risk of epilepsy in coiled group but higher late rebleeding risk in coiled group                                                                                                                                                                                                     Molyneux et al., Lancet 2005 \[[@B18]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*1070)                                                                                                                                                  (*N =*1073)                                                                                                Secondary outcomes: rebleeding, quality of life at 1-year (Euroqol), frequency of epilepsy, cost effectiveness, neuropsychological outcomes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  The barrow ruptured aneurysm trial                                                                                                                                                                                                                                                  Randomized, open-label, prospective, single-center study                                                                                                        Surgical clipping\                                                                                                                                           Endovascular coiling\                                                                                      Primary outcome: 1-year mRS \> 2                                                                                                                                                                                                                                                             Poor outcome in 33.7% of clipped and 23.2% of coiled patients (*P =*0.02)                                                                                                                                                                                                                                                                                                                                                                                               McDougall et al., J Neurosurg 2012 \[[@B16]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*238)                                                                                                                                                   (*N =*233)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Lipid peroxidation inhibitor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand                                                                                             Double-blind, randomized, vehicle-controlled study in men and women with aneurysmal SAH                                                                         Tirilazad 0.6 mg/kg/\                                                                                                                                        Placebo containing citrate vehicle\                                                                        Primary outcome: Symptomatic vasospasm Secondary outcome: 3-month GOS, NIHSS, infarct volume on head CT                                                                                                                                                                                      The subgroup 6 mg/kg treatment arm had reduced mortality (*P =*NS) and better 3-month GOS (*P =*NS) compared to placebo. Less symptomatic vasospasm in 6 mg/kg group, but not significant. Men showed more benefit than women. No significant improvement with lower dosing groups                                                                                                                                                                                      Kassell et al., J Neurosurg 1996 \[[@B77]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*257)\                                                                                                                                                  (*N =*253)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                      Tirilazad 2 mg/kg/d\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*249)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                      Tirilazad 6 mg/kg/d\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*256)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                      up to 11 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America                                                                                                                Double-blind, randomized, vehicle-controlled study in men and women with aneursymal SAH                                                                         Tirilazad 2 mg/kg/d\                                                                                                                                         Placebo containing citrate vehicle\                                                                        Primary outcome: mortality at 76 days Secondary outcome: 3-month GOS and NIHSS, infarct volume on head CT symptomatic vasospasm, incidence, and severity of angiographic vasospasm                                                                                                           No difference in mortality, favorable GOS outcome, or employment between groups. No differences in symptomatic or angiographic vasospasm                                                                                                                                                                                                                                                                                                                                Haley et al., J Neurosurg 1997 \[[@B78]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*298)\                                                                                                                                                  (*N =*300)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                      Tirilazad 6 mg/kg/d\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*299)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                      up to 11 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part I a cooperative study in Europe, Australia, New Zealand, and South Africa                                                                 Double-blind, randomized, vehicle-controlled study in women with aneurysmal SAH                                                                                 Tirilazad mesylate 15 mg/kg/d IV hours for 11 days\                                                                                                          Placebo containing citrate vehicle\                                                                        Primary outcome: 91-day mortality Secondary outcome: 3-month GOS, clinical vasospasm, use of hypervolemic hypertensive therapy, neurological worsening from vasospasm, cerebral infarction, use of angioplasty, safety endpoints                                                             Mortality rates and 3-month GOS not different between groups. Lower symptomatic vasospasm in tirilazad group (24.8% versus 33.7% in placebo group, *P =*0.005). Cerebral infarction 8% in treatment group versus 13% in placebo group (*P \<*0.04)                                                                                                                                                                                                                      Lanzino et al., J Neurosurg 1999 \[[@B29]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*405)                                                                                                                                                   (*N =*414)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneursymal subarachnoid hemorrhage. Part II a cooperative study in North America                                                                                                   Double-blind, randomized, vehicle-controlled study in women with aneurysmal SAH                                                                                 Tirilazad mesylate 15 mg/kg/d IV up to 11 days\                                                                                                              Placebo containing citrate vehicle\                                                                        Primary outcome: mortality at 91 days in WFNS grade IV-V patients Secondary outcomes: 3 month GOS or clinical vasospasm 1--14 days from dosing, use of hypervolemic hypertensive therapy, neurological worsening from vasospasm, cerebral infarction, use of angioplasty, safety endpoints   No differences in mortality when analyzing the entire population. No difference in GOS, symptomatic vasospasm, vasospasm severity. In WFNS grades IV-V, lower mortality in treatment group (24.6% versus 43.4% in placebo, *P =*0.016). In WFNS I--III improved GOS in placebo group (83.3% versus 76.7% in treatment group, *P =*0.04)                                                                                                                                 Lanzino and Kassell, J Neurosurg 1999 \[[@B79]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*410)                                                                                                                                                   (*N =*413)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Thrombolytics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Prevention of delayed ischemic deficits after aneurysmal subarachnoid hemorrhage by intrathecal bolus injection of tissue plasminogen activator (rTPA)                                                                                                                              Prospective, controlled trial of Fisher III clipped SAH patients                                                                                                rTPA 10 mg IV intracisternal immediately following aneurysm clipping ± 5--10 mg IV TPA intraventricularly in patients with IVH\                              No TPA instillation\                                                                                       Primary outcome: clinical delayed ischemic deficits attributed to vasospasm Secondary outcome: 3-month GOS                                                                                                                                                                                   Significantly less transient and permanent delayed ischemic deficits and better GOS in rTPA group                                                                                                                                                                                                                                                                                                                                                                       Seifert et al., Acta Neurochir 1994 \[[@B30]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*52)                                                                                                                                                    (*N =*68)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm                                                                                                                                                                   Randomized, double-blinded, placebo-controlled, multicenter study                                                                                               rTPA 10 mg intracisternal at the time of aneurysm clipping\                                                                                                  Placebo vehicle (*N =*49)                                                                                  Primary outcome: angiographic vasospasm Secondary outcome: mortality, 3-month GOS, symptomatic vasospasm, clot clearance on CT, TCD velocities, use of HHH on angioplasty to treat vasospasm                                                                                                 No difference in angiographic vasospasm, vasospasm treatment, TCD velocities, mortality, or 3-month GOS                                                                                                                                                                                                                                                                                                                                                                 Findlay, Neurosurgery 1995 \[[@B80]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*51)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Efficacy of low-dose tissue-plasminogen activator intracisternal administration for the prevention of cerebral vasospasm after subarachnoid hemorrhage                                                                                                                              Randomized, controlled trial                                                                                                                                    Intermittent Tisokinase 960,000 IU via cisternal drain\                                                                                                      Control (standard treatment)\                                                                              Primary outcome: clearance of subarachnoid clots by HCT\                                                                                                                                                                                                                                     Subarachnoid clot by HCT and delayed cerebral ischemia were significantly less in the treatment groups compared to control (*P \<*0.05). The intermittently treated group had better neurological outcomes than the control group (*P \<*0.05)                                                                                                                                                                                                                          Yamamoto et al., World Neurosurgery 2010 \[[@B31]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*20)\                                                                                                                                                   (*N =*20)                                                                                                  Secondary outcome: delayed cerebral ischemia, 3-month mRS and GOS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                      Continuous infusion Tisokinase 1920 IU/h × 48 h via cisternal drain\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*20)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Anti-platelets                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Dipyridamole and postoperative ischemic deficits in aneurysmal subarachnoid hemorrhage                                                                                                                                                                                              Randomized, placebo-controlled, single-blind controlled trial                                                                                                   Dipyridamole 100 mg PO qd or 10 mg/day IV × 3-months\                                                                                                        Placebo\                                                                                                   Primary outcome: 3-month GOS\                                                                                                                                                                                                                                                                No differences in 3-month GOS or delayed neurological deterioration                                                                                                                                                                                                                                                                                                                                                                                                     Shaw et al., J Neurosurg 1985 \[[@B81]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*336)                                                                                                                                                   (*N =*314)                                                                                                 Secondary outcome: neurological deterioration following aneurysm repair                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Randomized controlled trial of acetylsalicylic Acid in aneurysmal subarachnoid hemorrhage: the MASH study                                                                                                                                                                           Randomized controlled pilot study; factorial design (magnesium versus placebo and ASA versus placebo, separated a priori)                                       Aspirin 100 mg PR qd × 14 days within 12 hours of aneurysm occlusion.\                                                                                       Placebo\                                                                                                   Primary outcome: delayed ischemic neurological deficits within 3-months of SAH consisting of HCT infarcts plus clinical decline\                                                                                                                                                             No difference in delayed ischemic events, CT infarction, or 3-month outcomes                                                                                                                                                                                                                                                                                                                                                                                            Van den Bergh, Stroke 2006 \[[@B82]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*87)                                                                                                                                                    (*N =*74)                                                                                                  Secondary outcome:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              new CT infarcts of any cause, postop hemorrhage, mRS ≥ 4, mRS ≥ 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Cilostazol improves outcome after subarachnoid hemorrhage: a preliminary report                                                                                                                                                                                                     Randomized, single-blind, prospective, multicenter study                                                                                                        Cilostazol 100 mg PO BID\                                                                                                                                    Control (usual care)\                                                                                      Primary outcome: symptomatic vasospasm and cerebral infarction, discharge mRS                                                                                                                                                                                                                No difference in symptomatic vasospasm or cerebral infarction. mRS at discharge better in treatment group (1.5 versus 2.6 in controls, *P =*0.041)                                                                                                                                                                                                                                                                                                                      Suzuki et al., Cerebrovasc Dis 2011 \[[@B19]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*49)                                                                                                                                                    (*N =*51)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Steroids                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Effect of fludrocortisone acetate in patients with subarachnoid hemorrhage                                                                                                                                                                                                          Randomized, placebo controlled, multicenter trial                                                                                                               Fludrocortisone 400 mcg/day BID × 12 days PO or IV\                                                                                                          Placebo\                                                                                                   Primary outcome:\                                                                                                                                                                                                                                                                            Treatment reduced negative sodium balance (*P =*0.014) but did not affect plasma volume. No significant difference in cerebral ischemia (22% versus 31% in controls, *P =*0.349). Similar outcome in each group                                                                                                                                                                                                                                                         Hasan et al., Stroke 1989 \[[@B83]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*46)                                                                                                                                                    (*N =*45)                                                                                                  plasma volume change, fluid balance, sodium balance\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Secondary outcome: delayed cerebral ischemia within 28 days and 28-day GOS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  A randomized controlled trial of hydrocortisone against hyponatremia in patients with aneurysmal subarachnoid hemorrhage                                                                                                                                                            Randomized, placebo-controlled study                                                                                                                            Hydrocortisone 300 mg q 6 h × 10 d then taper over 4 d\                                                                                                      Placebo\                                                                                                   Primary outcome: hyponatremia\                                                                                                                                                                                                                                                               Less sodium excretion and urine volume in treatment group (*P =*0.04). No significant differences in vasospasm or mRS                                                                                                                                                                                                                                                                                                                                                   Katayama et al.,\
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*35)                                                                                                                                                    (*N =*36)                                                                                                  \< 140 mmol/L\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Stroke 2007 \[[@B84]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Secondary outcome:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              30-day mRS, symptomatic vasospasm                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Randomized, double-blind, placebo-controlled, pilot trial of high-dose methylprednisolone in aneurysmal subarachnoid hemorrrhage                                                                                                                                                    Randomized, double-blind, placebo-controlled, single center study                                                                                               Methylprednisolone 16 mg/kg IV qd × 3 days\                                                                                                                  Placebo\                                                                                                   Primary outcome: symptomatic vasospasm and infarct on HCT\                                                                                                                                                                                                                                   No significant difference in symptomatic vasospasm or infarct on HCT. No difference in 1-year GOS or delayed ischemic deficits at 3-months. Poor outcome by functional outcome scale was reduced in treatment group (*P =*0.02)                                                                                                                                                                                                                                         Gomis et al.,\
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*49)                                                                                                                                                    (*N =*46)                                                                                                  Secondary Outcomes: 1 year GOS, functional outcome scale, and severity of delayed ischemic deficits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  J Neurosurg 2010 \[[@B20]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Transfusion/erythropoietin/albumin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a phase II randomized, double-blind, placebo-controlled trial                                                                                               Phase II randomized, double-blind, placebo-controlled trial                                                                                                     Erythropoietin IV (30,000 u) every 48 h for a total of 90,000 U\                                                                                             Placebo\                                                                                                   Primary outcome: incidence, duration and severity of TCD vasospasm; duration of impaired autoregulation by TCD\                                                                                                                                                                              No differences in incidence of TCD vasospasm or adverse events. Treatment group had less severe TCD vasospasm (*P =*−0.037), reduced delayed ischemic deficits/delayed cerebral infarcts (*P =*0.001), and shortened duration of impaired autoregulation (*P \<*0.001) and more favorable discharge outcome (*P =*0.039)                                                                                                                                                Tseng et al.,\
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*40)                                                                                                                                                    (*N =*40)                                                                                                  Secondary outcome: incidence of delayed ischemic deficits, mRS, GOS, and NIHSS at discharge and 6-months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             J Neurosurg 2009 \[[@B21]\]

  Prospective, randomized trial of higher goal hemoglobin after SAH                                                                                                                                                                                                                   Prospective, randomized pilot safety, and feasibility study                                                                                                     Packed RBC transfusion to goal Hgb 11.5 g/dL\                                                                                                                Packed RBC transfusion to goal Hgb 10 g/dL\                                                                Primary outcomes: days of core temp \> 100.4 F, ventilator-free days, hemoglobin level\                                                                                                                                                                                                      Higher target Hgb resulted in more transfusions. No difference in safety endpoints. Number of MRI infarcts, NIHSS, and mRS similar between both groups at all timepoints                                                                                                                                                                                                                                                                                                Naidech et al., Neurocrit Care 2010 \[[@B85]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*21)                                                                                                                                                    (*N =*23)                                                                                                  Secondary outcomes: NIHSS, mRS, and MRI at 14 days, mRS at 28 days and 3-months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  The Albumin in Subarachnoid Hemorrhage multicenter pilot clinical trial: safety and neurologic outcomes (ALISAH)                                                                                                                                                                    Open label, dose escalation study                                                                                                                               Albumin in 3 tier doses: 0.625 g/kg/d (*N =*20), 1.25 g/kg/d (*N =*20), 1.875 g/kg/d (*N =*7) × 7 days\                                                      NA                                                                                                         Primary outcomes: severe to life threatening heart failure, anaphylaxis\                                                                                                                                                                                                                     Doses up to 1.25 g/kg/d × 7 days tolerated without dose-limiting complications. Trend toward better outcomes in 1.25 g/kg/d dose compared to 0.625 g/kg/d                                                                                                                                                                                                                                                                                                               Suarez et al.,\
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*47 total)                                                                                                                                                                                                                                                         Secondary outcomes: functional outcome at 3-months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Stroke 2012 \[[@B86]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Vasodilators---CRGP and endothelin receptor antagonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Effect of calcitonin-gene-related peptide in patients with delayed postoperative cerebral ischemia after aneurysmal subarachnoid hemorrhage                                                                                                                                         Randomized, single-blind, controlled, multicenter study                                                                                                         Calcitonin-related gene peptide (0.6mcg/min) × 10 days\                                                                                                      Standard medical therapy\                                                                                  Primary outcome: 3-month GOS                                                                                                                                                                                                                                                                 No difference in 3-month GOS. Hypotension common in treatment group.                                                                                                                                                                                                                                                                                                                                                                                                    Bell, European CGRP in subarachnoid Hemorrhage study group, Lancet 1992 \[[@B87]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*62)                                                                                                                                                    (*N =*55)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal SAh undergoing surgical clipping: a randomized, double-blind, placebo-controlled phase 3 trial\                                                                                                         Phase 3 randomized placebo-controlled double-blinded                                                                                                            Clazosentan\                                                                                                                                                 Placebo\                                                                                                   Primary outcomes: cerebral vasospasm-related morbidity (DCI/DIND/vasospasm therapy), all-cause mortality at 6 weeks\                                                                                                                                                                         No effect on primary endpoint (21% in clazosentan group and 25% in placebo group *P =*NS). Poor outcome (GOSE) in 29% clazosentan and 25% placebo group                                                                                                                                                                                                                                                                                                                 MacDonald et al., Lancet Neuol 2011 \[[@B32]\]
  (CONSCIOUS 2)                                                                                                                                                                                                                                                                                                                                                                                                                                       (5 mg/h IV up to 14 days)\                                                                                                                                   (*N =*389)                                                                                                 Secondary outcomes: 12-week GOSE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*748)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling\                                                                                                                                                                Phase 3 randomized placebo-controlled double-blinded;\                                                                                                          Clazosentan\                                                                                                                                                 Placebo\                                                                                                   Primary outcomes: cerebral vasospasm related morbidity (DCI/DIND/vasospasm therapy), all-cause mortality at 6 weeks\                                                                                                                                                                         Clazosentan 15 mg/h significantly reduced vasospasm-related morbidity/all-cause mortality at 6 weeks but did not improve long-term outcome\                                                                                                                                                                                                                                                                                                                             MacDonald et al., Stroke 2012 \[[@B33]\]
  (CONSCIOUS 3)                                                                                                                                                                                                                                                                       terminated early for futility (planned *N =*1500)                                                                                                               (5 or 15 mg/h IV up to 14 days)\                                                                                                                             (*N =*189)                                                                                                 Secondary outcomes: 12-week GOSE                                                                                                                                                                                                                                                             Primary outcome: 24% in clazosentan 5 mg/h and 27% in placebo group *P =*NS and 15% in clazosentan 15 mg/h *P =*0.007\                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*194)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Poor outcome in 25% of clazosentan 5 mg/h, 28% clazosentan 15 mg/h, and 24% of placebo group *P =*NS.                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Hypertensive, hypervolemic therapy (prophylactic)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: A randomized controlled trial                                                                                                                                                                  Randomized, controlled, single-center study                                                                                                                     High-volume management (with colloid and crystalloid) to target PADP ≥ 14 mmHg or CVP ≥ 8 mmHg\                                                              Normal volume management (with colloid and crystalloid) to target PADP ≥ 7 mmHg or CVP ≥ 5 mmHg\           Primary outcome: CBF by Xenon CT and blood volume by tagged RBC\                                                                                                                                                                                                                             High-volume management patients received significantly more fluid but there was no effect on net fluid balance or blood volume. No difference in CBF or vasospasm                                                                                                                                                                                                                                                                                                       Lennihan et al.,\
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*41)                                                                                                                                                    (*N =*41)                                                                                                  Secondary outcomes: symptomatic vasospasm, medical complications, GOS and 3, 6, and 12 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Stroke 2000 \[[@B88]\]

  Prophylactic hyperdynamic postoperative fluid therapy after aneurysmal subarachnoid hemorrhage: a clinical, prospective, randomized, controlled trial                                                                                                                               Randomized, controlled Prospective, trial of Hunt Hess I--III patients                                                                                          Hypertensive (MAP 20 mmHg greater than pre-op), hypervolemic (CVP 8--12 mmHg) and hemodilutional (Hct 30--35%) therapy\                                      Normovolemic crystalloid fluid therapy until day 12\                                                       Primary outcome: TCD vasospasm, CBF by SPECT on day 12\                                                                                                                                                                                                                                      No differences in TCD vasospasm or SPECT CBF. No difference in 1-year GOS, SPECT, or neuropsych outcomes                                                                                                                                                                                                                                                                                                                                                                Egge et al.,\
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*16)                                                                                                                                                    (*N =*16)                                                                                                  Secondary outcomes: 1 year GOS, neuropsych outcomes, and SPECT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Neurosurgery 2001 \[[@B89]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Magnesium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Intravenous magnesium sulfate for aneurysmal subarachnoid hemorrhage (IMASH): a randomized double-blinded, placebo-controlled, multicenter phase III trial                                                                                                                          Randomized double-blinded, placebo-controlled, multicenter phase III trial.                                                                                     MgSO~4~ IV infusion to 2x baseline value (20 mmol over 30 minutes then continuous infusion of 80 mmol/d × 14 days; maximum allowed serum Mg of 2.5 mmol/L\   Equivalent volume of normal saline infusion. Occasional changes in infusion rates to maintain blinding.\   Primary outcome: 6-month GOSE 5--8\                                                                                                                                                                                                                                                          Favorable 6-month GOSE (5--8) 64% of Mg group and 63% placebo (*P =*NS)\                                                                                                                                                                                                                                                                                                                                                                                                Wong et al.,\
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*169)                                                                                                                                                   (*N =*158)                                                                                                 Secondary outcome: clinical vasospasm during initial 2 weeks, 6-month mRS, Barthel Index, and Short Form 36                                                                                                                                                                                  No difference in mRS, Barthel, Short Form 36, or clinical vasospasm. No subgroup differences                                                                                                                                                                                                                                                                                                                                                                            Stroke 2010 \[[@B54]\]

  Magnesium for aneurysmal subarachnoid hemorrhage (MASH-2): a randomized placebo-controlled trial                                                                                                                                                                                    Randomized, double-blind, placebo controlled, multicenter, phase III trial                                                                                      MgSO~4~ IV 64 mmol/day\                                                                                                                                      Placebo\                                                                                                   Primary outcome: 3-month mRS 4--6                                                                                                                                                                                                                                                            No difference in poor outcome in the MgSO~4~ group (26.2% versus 25.3% in placebo group)                                                                                                                                                                                                                                                                                                                                                                                Mees et al.,\
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*606)                                                                                                                                                   (*N =*507)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Lancet 2012 \[[@B49]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Adrenergic blockade                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Beneficial effects of adrenergic blockade in patients with subarachnoid hemorrhage                                                                                                                                                                                                  Randomized controlled trial                                                                                                                                     Phentolamine 20 mg q 3 h + propranolol 80 mg q 8 × 3 weeks\                                                                                                  Placebo\                                                                                                   Primary outcome: neurological deficit at 28 days                                                                                                                                                                                                                                             Trend toward less neurological deficit in the treated group (*P =*0.053)                                                                                                                                                                                                                                                                                                                                                                                                Walter et al.,\
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*68)                                                                                                                                                    (*N =*66)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMJ 1982 \[[@B90]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Endovascular therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Effect of prophylactic transluminal balloon angioplasty on cerebral vasospasm and outcome in patients with Fisher grade III subarachnoid hemorrhage: results of a phase II multicenter, randomized clinical trial                                                                   Unblinded, randomized phase II trial of Fisher III and Fisher III + IV SAH patients after clipping or coiling within 96 h of rupture                            Balloon angioplasty of bilateral A1, M1, P1, basilar, intradural vertebral artery, and supraclinoid ICA. Protocol later revised to exclude A1 and P1\        No prophylactic balloon angioplasty\                                                                       Primary outcome: 3-month GOS\                                                                                                                                                                                                                                                                Nonsignificant difference in delayed ischemic neurological deficits but less therapeutic angioplasty required in treatment group (*P =*0.03). No significant difference in GOS outcomes. LOS similar. Four patients had procedure related vessel perforation, three of whom died                                                                                                                                                                                        Zwienenberg-Lee et al., Stroke 2008 \[[@B91]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*85)                                                                                                                                                    (*N =*85)                                                                                                  Secondary outcome: delayed ischemic neurological deficit, TCD vasospasm, ICU, and hospital length of stay                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Rho kinase inhibitor---fasudil                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial                                                                                                                                      Randomized, placebo controlled, double-blind, multicenter study in Hunt Hess I--IV clipped SAH patients                                                         Fasudil (AT877)\                                                                                                                                             Placebo\                                                                                                   Primary outcome: reduction of incidence or severity of angiographic vasospasm, reduction of incidence and size of low-density CT lesions due to vasospasm, reduction of incidence of symptomatic vasospasm, poor outcome (1-month GOS) due to vasospasm                                      Fasudil significantly reduced angiographic vasospasm (38% in treatment group versus 61% in placebo group, *P =*0.0023), infarcts reduced (16% in treatment versus 38% in placebo group, *P =*0.0013) and symptomatic vasospasm reduced (35% in treatment versus 50% in placebo, *P =*0.0247). Poor outcome (GOS 1--4) attributable to vasospasm occurred in 12% of treatment group and 26% of placebo group (*P =*0.0152). No serious adverse events in fasudil group   Shibuya et al.,\
                                                                                                                                                                                                                                                                                                                                                                                                                                                      30 mg IV over 30 minutes, TID × 14 days\                                                                                                                     (*N =*136)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      J Neurosurg 1992 \[[@B23]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*131)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine                                                                                                                                           Randomized, open label, multicenter study of SAH Hunt-Hess grade I--IV clipped patients                                                                         Fasudil 30 mg IV TID × 14 days\                                                                                                                              Nimodipine 1-2 mg/h × 14 days\                                                                             Primary outcome: symptomatic vasospasm or infarct on HCT\                                                                                                                                                                                                                                    No difference in symptomatic vasospasm or HCT infarcts. Improved GOS outcomes in fasudil group (good outcome in 74.5% versus 61.7% in nimodipine group, *P =*0.040)                                                                                                                                                                                                                                                                                                     Zhao et al.,\
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*63)                                                                                                                                                    (*N =*66)                                                                                                  Secondary outcome:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Neurol Med Chir (Tokyo) 2011 \[[@B22]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              1-month GOS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Intensive insulin therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  The effect of intensive insulin therapy on infection rate, vasospasm, neurologic outcome and mortality in neurointensive care unit after intracranial aneurysm clipping in patients with acute subarachnoid hemorrhage: a randomized prospective Pilot trial                        Randomized, controlled study                                                                                                                                    Intensive Insulin Infusion (80--120 mg/dL) × 14 d\                                                                                                           Conventional insulin infusion (glucose 80--220 mg/dL) × 14 d\                                              Primary outcome: infection\                                                                                                                                                                                                                                                                  Higher infection rate in the conventional group (42% versus 27% in intensive group, *P* \< 0.001). Similar vasospasm, mortality, and mRS at 6 months                                                                                                                                                                                                                                                                                                                    Bilotta et al.,\
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*40)                                                                                                                                                    (*N* = 38)                                                                                                 Secondary outcomes: vasospasm, 6-month mortality, and mRS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            J Neurosurg Anesthesiol 2007 \[[@B55]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Hypothermia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Mild intraoperative hypothermia during surgery for intracranial aneurysm (IHAST)                                                                                                                                                                                                    Randomized, prospective, partially blinded, controlled, multicenter trial of WFNS grade I--III SAH patients                                                     Intraoperative hypothermia (target 33°C with surface cooling)\                                                                                               Intraoperative normothermia (target 36.5°C)\                                                               Primary outcome: GOS at 90 days\                                                                                                                                                                                                                                                             No difference in 90 day GOS. Good GOS in 66% of hypothermia versus 63% of control patients (*P =*NS). No differences in death, length of stay, or discharge disposition. Postoperative bacteremia more common in the hypothermia group (5% versus 3%, *P =*0.05)                                                                                                                                                                                                        Todd et al.,\
                                                                                                                                                                                                                                                                                                                                                                                                                                                      (*N =*499)                                                                                                                                                   (*N =*501)                                                                                                 Secondary outcomes: 90-day mRS, Barthel Index, NIHSS, neuropsych testing, adverse events                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             NEJM 2005 \[[@B57]\]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Randomized controlled trials assessing neurologic outcomes after cardiac arrest---completed trials.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Trial name                                                                                                                                                                   Study design                                                                                                                                            Treatment group                                                                                                  Control group                                                                 Outcome measure                                                                                                                                                                                                                                                                                                  Results                                                                                                                                                                                                                                                                                                                                                                                                                                                 Reference
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------
  Calcium channel blockers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Effects of nimodipine on cerebral blood flow and cerebrospinal fluid pressure after cardiac arrest: correlation with neurologic outcome                                      Randomized, double-blind study                                                                                                                          Nimodipine IV 0.25 mcg/kg/min\                                                                                   Placebo\                                                                      Primary outcome: CBF measured by Xenon CT\                                                                                                                                                                                                                                                                       Higher CBF in nimodipine group in first 4 hours after arrest (*P \<*0.05) but no difference at 24 hours. No difference in neurological outcomes                                                                                                                                                                                                                                                                                                         Forsman et al.,\
                                                                                                                                                                                                                                                                                                                                       (*N =*25)                                                                                                        (*N =*26)                                                                     Secondary outcomes: ICP, neurological disability                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Anesth Analg 1989 \[[@B43]\]

  Neuropsychological sequelae of cardiac arrest                                                                                                                                Randomized, double-blind, placebo-controlled, study of out-of-hospital ventricular fibrillation                                                         Nimodipine 10 mcg/kg IV then 0.5 mcg/kg/min × 24 hours\                                                          Placebo\                                                                      Primary outcome: 3- and 12-month neuropsychological and cognitive batteries                                                                                                                                                                                                                                      No difference in neuropsychological or cognitive outcome between groups                                                                                                                                                                                                                                                                                                                                                                                 Roine et al.,\
                                                                                                                                                                                                                                                                                                                                       (*N =*35)                                                                                                        (*N =*33)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              JAMA 1992 \[[@B44]\]

  A randomized clinical study of a calcium-entry blocker (lidoflazine) in the treatment of comatose survivors of cardiac arrest                                                Randomized, double-blind, placebo-controlled, multicenter study                                                                                         Lidoflazine 1 mg/kg loading dose then 0.25 mg/kg at 8 and 16 hours after resuscitation\                          Placebo\                                                                      Primary outcome: Pittsburgh Cerebral Performance Scale at 6 months\                                                                                                                                                                                                                                              No difference in 6-month neurological outcome or mortality between groups                                                                                                                                                                                                                                                                                                                                                                               Brain Resuscitation Clinical Trial II Study Group, NEJM 1991 \[[@B92]\]
                                                                                                                                                                                                                                                                                                                                       (*N =*259)                                                                                                       (*N =*257)                                                                    Secondary outcomes: mortality, complications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Nimodipine after resuscitation from out-of-hospital ventricular fibrillation: a placebo-controlled, double-blind, randomized trial                                           Randomized, double-blind, placebo-controlled, study of out-of-hospital ventricular fibrillation                                                         Nimodipine 10 mcg/kg IV then 0.5 mcg/kg/min × 24 hours\                                                          Placebo\                                                                      Primary outcome: survival, 1-year GOS\                                                                                                                                                                                                                                                                           No difference in the survival rate, GOS at 3 or 12 months. No difference in minimental state exam, activities of daily living, or seizures                                                                                                                                                                                                                                                                                                              Roine et al.,\
                                                                                                                                                                                                                                                                                                                                       (*N =*75)                                                                                                        (*N =*80)                                                                     Secondary outcomes: death related to anoxic encephalopathy, GCS at 24 hours and 1 week, 3- and 12-month mini-mental state exam, activities of daily living, Barthel index, neurological exam, seizure, SPECT, myocardial infarction, arrhythmias                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         JAMA 1990 \[[@B45]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Neuroprotective                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Coenzyme Q 10 combined with mild hypothermia after cardiac arrest: a preliminary study                                                                                       Randomized, placebo-controlled, double-blind, single-center study of out-of-hospital cardiac arrest                                                     Hypothermia 35-36°C × 24 hours + Coenzyme Q 10 250 mg PO × 1 then 150 mg PO TID\                                 Hypothermia 35-36°C × 24 hours + Placebo\                                     Primary outcome: survival to ICU discharge\                                                                                                                                                                                                                                                                      3-month survival was 68% in the treatment group and 29% in the control group (*P =*0.0413). There was no significant difference in survival until discharge or GOS outcome                                                                                                                                                                                                                                                                              Damian et al., Circulation 2004 \[[@B36]\]
                                                                                                                                                                                                                                                                                                                                       (*N =*25)                                                                                                        (*N =*24)                                                                     Secondary outcomes: 3-month survival, 3-month GOS, S100 levels                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Thrombolytics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  A pilot randomized trial of thrombolysis in cardiac arrest (the TICA trial)                                                                                                  Randomized, double-blind, placebo controlled, single-center, feasibility trial for out-of-hospital cardiac arrest                                       Tenecteplase 50 mg IV × 1\                                                                                       Placebo\                                                                      Primary outcome: ROSC\                                                                                                                                                                                                                                                                                           ROSC in 42% of tenecteplase and 6% of placebo group. No difference in survival to hospital discharge                                                                                                                                                                                                                                                                                                                                                    Fatovich et al., Resuscitation 2004 \[[@B47]\]
                                                                                                                                                                                                                                                                                                                                       (*N =*19)                                                                                                        (*N =*16)                                                                     Secondary outcomes: survival to ED, ICU and hospital discharge                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Thrombolysis during resuscitation for out-of-hospital cardiac arrest                                                                                                         Randomized, double-blind, controlled, multicenter study of out-of-hospital cardiac arrest                                                               Tenecteplase 0.5 mg/kg IV\                                                                                       Placebo\                                                                      Primary outcome: survival at 30 days\                                                                                                                                                                                                                                                                            No difference in 30-day survival, hospital admission, ROSC, 24-hour survival, discharge, or neurologic outcome. More intracranial hemorrhages in treatment group                                                                                                                                                                                                                                                                                        Böttiger et al., NEJM 2008 \[[@B46]\]
                                                                                                                                                                                                                                                                                                                                       (*N =*525)                                                                                                       (*N =*525)                                                                    Secondary outcomes: survival to admission, ROSC, 24-hour survival, survival to discharge, cerebral performance score at discharge                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Steroids and pressors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Vasopressin, epinephrine, and corticosteroids for In-hospital cardiac arrest                                                                                                 Randomized, double-blind, placebo-controlled, single-center study                                                                                       Vasopressin 20 IU IV + epinephrine 1 mg IV + methylprednisolone 40 mg IV followed by hydrocortisone\             Epinephrine + placebo\                                                        Primary outcome: ROSC, survival to discharge\                                                                                                                                                                                                                                                                    More ROSC in treatment group (81% versus 52%, *P =*0.003) and more survival to discharge (19% versus 4%, *P =*0.02)                                                                                                                                                                                                                                                                                                                                     Mentzelopoulos et al.,\
                                                                                                                                                                                                                                                                                                                                       (*N =*48)                                                                                                        (*N =*52)                                                                     Secondary outcomes: blood pressure after CPR, organ failure-free days, discharge Glasgow-Pittsburg cerebral performance scale                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Arch Intern Med 2009 \[[@B37]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Pressors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  A comparison of standard-dose and high-dose epinephrine in cardiac arrest outside the hospital                                                                               Randomized, double-blind, prospective, multi-center study                                                                                               Epinephrine 0.2 mg/kg IV\                                                                                        Epinephrine 0.02 mg/kg IV\                                                    Primary outcome: return of spontaneous circulation (ROSC), admission to the hospital\                                                                                                                                                                                                                            No difference in ROSC rates, admission, survival, or discharge neurological status                                                                                                                                                                                                                                                                                                                                                                      Brown et al., NEJM 1992 \[[@B93]\]
                                                                                                                                                                                                                                                                                                                                       (*N =*648)                                                                                                       (*N =*632)                                                                    Secondary outcome: cerebral performance scale at admission, and discharge                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Standard doses versus repeated high doses of epinephrine in cardiac arrest outside the hospital                                                                              Randomized, double-blind, prospective, single-center study                                                                                              Repeated epinephrine 5 mg IV\                                                                                    Repeated epinephrine 1 mg IV\                                                 Primary outcome: ROSC\                                                                                                                                                                                                                                                                                           No difference in ROSC, admission, discharge, or 6-month neurological outcomes                                                                                                                                                                                                                                                                                                                                                                           Choux et al., Resuscitation 1995 \[[@B94]\]
                                                                                                                                                                                                                                                                                                                                       (*N =*271)                                                                                                       (*N =*265)                                                                    Secondary outcomes: admission to the hospital, discharge, cerebral performance category at discharge and 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  A randomized, double-blind comparison of methoxamine and epinephrine in human cardiopulmonary arrest                                                                         Randomized, double-blind, single-center study                                                                                                           Methoxamine 40 mg bolus IV then 40 mg 4 minutes later\                                                           Epinephrine 2 mg bolus then 2 mg IV q 4 min\                                  Primary outcome: Mortality and Glasgow-Pittsburgh coma score\                                                                                                                                                                                                                                                    No difference in ROSC or neurologic outcome, initial resuscitation, or survival to discharge                                                                                                                                                                                                                                                                                                                                                            Patrick et al.,\
                                                                                                                                                                                                                                                                                                                                       (*N =*77)                                                                                                        (*N =*68)                                                                     Secondary outcomes: ROSC, successful resuscitation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Am J Respir Crit Care Med 1995 \[[@B95]\]

  Randomised comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation                                                               Randomized, double-blind, single-center, controlled study of out-of-hospital ventricular fibrillation patients who failed defibrillation                Vasopressin 40 IU IV\                                                                                            Epinephrine 1 mg IV\                                                          Primary outcome: survival to admission\                                                                                                                                                                                                                                                                          No significant difference in survival to admission but more vasopressin patients survived 24 hours (60% versus 20%, *P =*0.02). No difference in survival to discharge or GCS at discharge                                                                                                                                                                                                                                                              Lindner et al.,\
                                                                                                                                                                                                                                                                                                                                       (*N =*20)                                                                                                        (*N =*20)                                                                     Secondary outcome: 24-hour survival, survival to discharge, GCS at discharge                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Lancet 1997 \[[@B96]\]

  High-dose versus standard-dose epinephrine treatment of cardiac arrest after failure of standard therapy                                                                     Randomized, controlled, single-blind, multicenter study of patients who had failed on standard dose of epinephrine 0.5--1.0 mg IV                       Epinephrine 0.1 mg/kg IV up to 4 doses\                                                                          Epinephrine 0.01 mg/kg IV up to 4 doses\                                      Primary outcome: improvement in cardiac rhythm or ROSC\                                                                                                                                                                                                                                                          No differences in ROSC, survival, or neurologic function between groups                                                                                                                                                                                                                                                                                                                                                                                 Sherman et al., Pharmacotherarpy 1997 \[[@B97]\]
                                                                                                                                                                                                                                                                                                                                       (*N =*78)                                                                                                        (*N =*62)                                                                     Secondary outcomes: GCS at 6, 24, and 72 hours                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  A comparison of repeated high doses and repeated standard doses of epinephrine for cardiac arrest outside the hospital                                                       Randomized, controlled, prospective multicenter study                                                                                                   Epinephrine 5 mg IV up to 15 doses at 3-minute intervals\                                                        Epinephrine 1 mg IV up to 15 doses at 3-minute intervals\                     Primary outcome: ROSC, admission to the hospital, number of admissions after a single dose of epinephrine, hospital discharge\                                                                                                                                                                                   Significantly more ROSC in high dose group (40% versus 36% of control group, *P =*0.02) and more survival to admission (26.5% versus 23.6% of controls, *P =*0.05). No difference in survival to discharge or neurological status                                                                                                                                                                                                                       Gueugniaud et al., NEJM 1998 \[[@B98]\]
                                                                                                                                                                                                                                                                                                                                       (*N =*1677)                                                                                                      (*M* = 1650)                                                                  Secondary outcomes: survival, neurological outcome by GCS and cerebral performance scale                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Vasopressin versus epinephrine for in hospital cardiac arrest: a randomized controlled trial                                                                                 Randomized, controlled, triple-blind, multicenter study of in-hospital cardiac arrest for asystole, PEA, or refractory ventricular fibrillation         Vasopressin 40 IU IV (first pressor)\                                                                            Epinephrine 1 mg IV (first pressor)\                                          Primary outcome: survival for 1 hour\                                                                                                                                                                                                                                                                            No difference in survival at 1 hour or survival to hospital discharge. No difference in mini-mental state exam scores or cerebral performance scores                                                                                                                                                                                                                                                                                                    Stiell et al.,\
                                                                                                                                                                                                                                                                                                                                       (*N =*104)                                                                                                       (*N =*96)                                                                     Secondary outcomes: survival to hospital discharge, modified mini-mental state exam at discharge, cerebral performance score at discharge, ROSC, adverse events                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Lancet 2001 \[[@B99]\]

  A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation                                                                                Randomized, controlled, multicenter study of out-of-hospital cardiac arrest with ventricular fibrillation failing defibrillation, PEA, or asystole      Vasopressin 40 IU IV × 2 doses maximum\                                                                          Epinephrine 1 mg IV × 2 doses maximum\                                        Primary outcome: survival to hospital admission\                                                                                                                                                                                                                                                                 No difference in survival to admission among patients with ventricular fibrillation or PEA. Higher rates of hospital admission for asystole in vasopressin group (29% versus 20%, *P =*0.02) and hospital discharge (4.7% versus 1.5% with epinephrine, *P =*0.04). Patients who received rescue epinephrine after vasopressin had better survival to admission and discharge than the epinephrine alone group. No difference in cerebral performance   Wenzel et al.,\
                                                                                                                                                                                                                                                                                                                                       (*N =*589)                                                                                                       (*N =*597)                                                                    Secondary outcomes: survival to hospital discharge, cerebral performance score in survivors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              NEJM 2004 \[[@B100]\]

  Vasopressin and epinephrine versus epinephrine alone in cardiopulmonary resuscitation                                                                                        Randomized, controlled, multicenter trial                                                                                                               Epinephrine 1 mg IV + Vasopressin 40 IU IV\                                                                      Epinephrine 1 mg IV + Placebo\                                                Primary outcome: Survival to hospital admission\                                                                                                                                                                                                                                                                 No differences in survival to admission, ROSC, survival to discharge, 1-year survival, or good neurologic recovery                                                                                                                                                                                                                                                                                                                                      Gueugniaud et al., NEJM 2008 \[[@B101]\]
                                                                                                                                                                                                                                                                                                                                       (*N =*1442)                                                                                                      (*N =*1452)                                                                   Secondary outcomes: ROSC, survival to hospital discharge, good neurological recovery by cerebral performance scale, and GCS, 1-year survival                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Magnesium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Randomised trial of magnesium in in-hospital cardiac arrest (MAGIC trial)                                                                                                    Randomized, placebo-controlled, single-center study of cardiac arrest in the ICU or general ward                                                        Magnesium 2 g IV bolus then 8 g over 24 hours\                                                                   Placebo\                                                                      Primary outcome: ROSC\                                                                                                                                                                                                                                                                                           No difference in ROSC, 24-hour survival, survival to discharge, or GCS                                                                                                                                                                                                                                                                                                                                                                                  Thel et al.,\
                                                                                                                                                                                                                                                                                                                                       (*N =*76)                                                                                                        (*N =*80)                                                                     Secondary outcomes: 24-hour survival, survival to hospital discharge, GCS, and discharge Karnofsky                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Lancet 1997 \[[@B53]\]

  Magnesium in cardiac arrest (the MAGIC trial)                                                                                                                                Randomized, double-blind, placebo-controlled, single-center study of out-of-hospital cardiac arrest                                                     MgSO~4~ 5 g IV × 1\                                                                                              Placebo\                                                                      Primary outcome: ECG rhythm 2 minutes after drug, ROSC\                                                                                                                                                                                                                                                          No differences in ROSC or survival                                                                                                                                                                                                                                                                                                                                                                                                                      Fatovich et al., Resuscitation 1997 \[[@B50]\]
                                                                                                                                                                                                                                                                                                                                       (*N =*31)                                                                                                        (*N =*36)                                                                     Secondary outcomes: survival to ED, ICU, and hospital discharge                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Magnesium sulfate in the treatment of refractory ventricular fibrillation in the prehospital setting                                                                         Randomized, double-blind, placebo-controlled, multicenter study of prehospital ventricular fibrillation refractory to 3 shocks                          MgSO~4~ 2 g IV × 1\                                                                                              Placebo\                                                                      Primary outcome: ROSC\                                                                                                                                                                                                                                                                                           No difference in ROSC, survival to admission or discharge                                                                                                                                                                                                                                                                                                                                                                                               Allegra et al.,\
                                                                                                                                                                                                                                                                                                                                       (*N =*58)                                                                                                        (*N =*58)                                                                     Secondary outcomes: admission to hospital, hospital discharge                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Resuscitation 2001 \[[@B48]\]

  A randomized trial to investigate the efficacy of magnesium sulphate for refractory ventricular fibrillation                                                                 Randomized, double-blind, placebo-controlled trial of ventricular fibrillation refractory to 3 shocks                                                   MgSO~4~ 2--4 g IV × 1\                                                                                           Placebo\                                                                      Primary outcome: ROSC\                                                                                                                                                                                                                                                                                           No differences in ROSC or survival to discharge                                                                                                                                                                                                                                                                                                                                                                                                         Hassan et al.,\
                                                                                                                                                                                                                                                                                                                                       (*N =*52)                                                                                                        (*N =*53)                                                                     Secondary outcome: hospital discharge                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Emerg Med J 2002 \[[@B51]\]

  Randomized clinical trial of magnesium, diazepam, or both after out-of-hospital cardiac arrest                                                                               Randomized, double-blind, placebo-controlled factorial design study                                                                                     Tier 1: magnesium 2 g IV + placebo\                                                                              Placebo only\                                                                 Primary outcome: awakening at 3 months (comprehensible speech and command following)\                                                                                                                                                                                                                            No difference in neurological outcome between the 3 groups                                                                                                                                                                                                                                                                                                                                                                                              Longstreth et al., Neurology 2002 \[[@B52]\]
                                                                                                                                                                                                                                                                                                                                       (*N =*75)\                                                                                                       (*N =*75)                                                                     Secondary outcome: days to awakening, days to death, independent at 3 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                       Tier 2: diazepam 10 mg IV + placebo\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                       (*N =*75)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                       Tier 3: magnesium 2 g IV + Diazepam 10 g IV\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                       (*N =*75)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Insulin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Intravenous glucose after out-of-hospital cardiopulmonary arrest: a community-based randomized trial                                                                         Randomized, single-center controlled study                                                                                                              5% dextrose (D5W) infusion\                                                                                      0.45 saline infusion\                                                         Primary outcome: command following or comprehensible speech\                                                                                                                                                                                                                                                     No difference in neurological outcomes, or survival to admission or discharge                                                                                                                                                                                                                                                                                                                                                                           Longstreth et al., Neurology 1993 \[[@B102]\]
                                                                                                                                                                                                                                                                                                                                       (*N =*374)                                                                                                       (*N =*374)                                                                    Secondary outcomes: survival to hospital admission and discharge                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Strict versus moderate glucose control after resuscitation from ventricular fibrillation                                                                                     Randomized, controlled, multicenter study of out-of-hospital ventricular fibrillation cardiac arrest                                                    Strict glucose control (4--6 mmol/L) with insulin infusion × 48 hours\                                           Moderate glucose control (6--8 mmol/L) with insulin infusion × 48 hours\      Primary outcome: 30-day all-cause mortality after ROSC\                                                                                                                                                                                                                                                          No difference in 30-day mortality                                                                                                                                                                                                                                                                                                                                                                                                                       Oksanen et al., Intensive Care Med 2007 \[[@B56]\]
                                                                                                                                                                                                                                                                                                                                       (*N =*39)                                                                                                        (*N =*51)                                                                     Secondary outcomes: neuron-specific enolase levels at 24 and 48 hours                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Hypothermia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia                                                                                   Randomized, controlled, single-blind, prospective study                                                                                                 Hypothermia 33°C × 12 h\                                                                                         Normothermia 37°C\                                                            Primary outcome: discharge disposition\                                                                                                                                                                                                                                                                          Good discharge disposition in 49% of treatment group compared to 26% of normothermia group (*P =*0.046). No difference in adverse events                                                                                                                                                                                                                                                                                                                Bernard et al., NEJM 2002 \[[@B41]\]
                                                                                                                                                                                                                                                                                                                                       (*N =*43)                                                                                                        (*N =*34)                                                                     Secondary outcomes: adverse events, hemodynamic parameters                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest                                                                                          Randomized, controlled, single-blind, multicenter, prospective study                                                                                    Hypothermia 32--34°C × 24 h\                                                                                     Normothermia 37°C\                                                            Primary outcome: 6 month neurologic outcome using Pittsburgh cerebral performance scale\                                                                                                                                                                                                                         Hypothermia group had more favorable neurological outcome at 6 months (55% versus 39% of normothermia group, *P =*0.009). Less death in hypothermia group (41% versus 55% in normothermia group, *P =*0.02). No difference in complication rates                                                                                                                                                                                                        The hypothermia after cardiac arrest study group, NEJM 2002 \[[@B40]\]
                                                                                                                                                                                                                                                                                                                                       (*N =*137)                                                                                                       (*N =*138)                                                                    Secondary outcome: 6-month mortality, complications at 7 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Pilot randomized clinical trial of prehospital induction of mild hypothermia in out-of-hospital cardiac arrest patients with a rapid infusion of 4 degrees C normal saline   Randomized, controlled, safety and feasibility study of out-of-hospital cardiac arrest                                                                  2 L 4°C normal saline infusion\                                                                                  Standard care\                                                                Primary outcome: esophageal temperature, adverse events\                                                                                                                                                                                                                                                         Significant differences in temperature between groups (*P \<*0.001). No difference in awakening or hospital discharge                                                                                                                                                                                                                                                                                                                                   Kim et al.,\
                                                                                                                                                                                                                                                                                                                                       (*N =*63)                                                                                                        (*N =*62)                                                                     Secondary outcomes: awakening, hospital discharge                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Circulation 2007 \[[@B103]\]

  Prehospital therapeutic hypothermia for comatose survivors of cardiac arrest: a randomized controlled trial                                                                  Randomized controlled trail of out-of-hospital cardiac arrest                                                                                           4°C Ringers solution 30 mL/kg to target temperature 33°C\                                                        Conventional fluid therapy\                                                   Primary outcome: nasopharyngeal temperature\                                                                                                                                                                                                                                                                     Lower core temperature in the treatment group (*P \<*0.001). No difference in safety, mortality, or neurologic outcome                                                                                                                                                                                                                                                                                                                                  KÄmÄrÄinen et al., Acta Anaesthesiol Scand 2009 \[[@B104]\]
                                                                                                                                                                                                                                                                                                                                       (*N =*19)                                                                                                        (*N =*18)                                                                     Secondary outcomes: hospital mortality and cerebral performance scale                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Intra-arrest transnasal evaporative cooling: a randomized, prehospital, multicenter study (PRINCE: pre-rosc intranasal cooling effectiveness)                                Randomized, controlled, prospective, single-blind, multicenter study for out-of-hospital arrest                                                         Intra-arrest intranasal cooling with RhinoChill device + cooling at hospital arrival to 34°C\                    Standard care with cooling at hospital arrival to 34°C\                       Primary Outcome: adverse events, length of stay, mechanical ventilation days, ROSC, survival to discharge, discharge Pittsburgh cerebral performance scale.                                                                                                                                                      Time to target temperature was shorter in the intranasal cooling group (*P =*0.03). No difference in ROSC, survival of admitted patients, or neurologic outcome at discharge                                                                                                                                                                                                                                                                            Castrén et al., Circulation 2010 \[[@B105]\]
                                                                                                                                                                                                                                                                                                                                       (*N =*93)                                                                                                        (*N =*101)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Chest compressions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  A comparison of active compression-decompression cardiopulmonary resuscitation with standard cardiopulmonary resuscitation for cardiac arrests occurring in the hospital     Randomized, controlled, single center study                                                                                                             CPR using suction device (Ambu CardioPump)\                                                                      Standard CPR\                                                                 Primary outcome: ROSC\                                                                                                                                                                                                                                                                                           ROSC occurred in 62% of treatment group versus 30% of control group (*P \<*0.03) and 45% of treatment group survived 24 hours compared to 9% of control group (*P \<*0.004). GCS at 24 hours was better in the treatment group (*P \<*0.02)                                                                                                                                                                                                             Cohen et al.,\
                                                                                                                                                                                                                                                                                                                                       (*N =*29)                                                                                                        (*N =*33)                                                                     Secondary outcomes: 24-hour survival, hospital discharge, GCS at 24 hours                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                NEJM 1993 \[[@B38]\]

  The Ontario Trial of Active Compression-Decompression Cardiopulmonary Resuscitation for In-Hospital and\                                                                     Randomized, single-blind, multicenter controlled trial of prehospital and in-hospital cardiac arrest                                                    Active compression-decompression CPR using a suction device\                                                     Standard CPR\                                                                 Primary outcome: survival for 1 hour\                                                                                                                                                                                                                                                                            No differences in survival at 1 hour, survival until hospital discharge or mini-mental state exam for either prehospital or in-hospital arrest                                                                                                                                                                                                                                                                                                          Stiell et al.,\
  Prehospital Cardiac Arrest                                                                                                                                                                                                                                                                                                           (*N =*906)                                                                                                       (*N =*878)                                                                    Secondary outcome: survival to hospital discharge, modified mini-mental state exam, cerebral performance scale                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           JAMA 1996 \[[@B42]\]

  Cardiopulmonary resuscitation by chest compression alone or with mouth-to-mouth ventilation                                                                                  Randomized controlled study of out-of-hospital cardiac arrest                                                                                           Bystander chest compression plus mouth to mouth resuscitation\                                                   Bystander chest compressions alone\                                           Primary outcome: survival to hospital discharge\                                                                                                                                                                                                                                                                 Similar outcome with bystander chest compressions alone versus chest compressions with mouth to mouth                                                                                                                                                                                                                                                                                                                                                   Hallstrom et al.,\
                                                                                                                                                                                                                                                                                                                                       (*N =*279)                                                                                                       (*N =*241)                                                                    Secondary outcomes: admission to the hospital, neurological status                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       NEJM 2000 \[[@B106]\]

  Constant flow insufflations of oxygen as the sole mode of ventilation during out-of-hospital cardiac arrest                                                                  Randomized, controlled study of out-of-hospital cardiac arrest                                                                                          Constant flow insufflations of oxygen\                                                                           Standard endotracheal intubation and mechanical ventilation\                  Primary outcome: survival to ICU discharge\                                                                                                                                                                                                                                                                      No difference in ROSC, hospital admission or ICU discharge. Higher O~2~ sats in continuous flow insufflation group                                                                                                                                                                                                                                                                                                                                      Bertrand et al., Intensive Care Med 2006 \[[@B107]\]
                                                                                                                                                                                                                                                                                                                                       (*N =*487)                                                                                                       (*N =*457)                                                                    Secondary outcomes: ROSC, survival to hospital admission, spO~2~ \> 70%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Compression-only CPR or standard CPR in out-of-hospital cardiac arrest                                                                                                       Randomized, controlled, multicenter study of out-of-hospital cardiac arrest                                                                             Compression only CPR\                                                                                            Standard CPR\                                                                 Primary outcome: 30 day survival\                                                                                                                                                                                                                                                                                Similar 30-day survival, 1-day survival and survival to hospital discharge                                                                                                                                                                                                                                                                                                                                                                              Svensson et al.,\
                                                                                                                                                                                                                                                                                                                                       (*N =*620)                                                                                                       (*N =*656)                                                                    Secondary outcomes: 1 day survival, ROSC, survival to hospital discharge                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 NEJM 2010 \[[@B108]\]

  CPR with chest compression alone or with rescue breathing                                                                                                                    Randomized, controlled, multicenter study of out-of-hospital cardiac arrest                                                                             Chest compressions alone\                                                                                        Chest Compressions + Rescue breathing (2 breaths to 15 chest compressions)\   Primary outcome: survival to hospital discharge\                                                                                                                                                                                                                                                                 No difference in survival to hospital discharge or in neurologic outcome. Trend toward improved survival at discharge in those with cardiac cause of arrest and shockable rhythm (*P =*0.09)                                                                                                                                                                                                                                                            Rea et al.,\
                                                                                                                                                                                                                                                                                                                                       (*N =*981)                                                                                                       (*N =*960)                                                                    Secondary outcomes: discharge cerebral performance Score,\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               NEJM 2010 \[[@B109]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ROSC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  A trial of an impedance threshold device in out-of-hospital cardiac arrest                                                                                                   Randomized, controlled, double-blinded, multicenter study of out-of-hospital cardiac arrest                                                             Impedance threshold device (ITD) which increasing negative intrathoracic pressure and improves cardiac output\   Sham ITD\                                                                     Primary outcome: survival to hospital discharge with mRS 0--3\                                                                                                                                                                                                                                                   No difference in survival with good mRS                                                                                                                                                                                                                                                                                                                                                                                                                 Aufderheide et al., NEJM 2011 \[[@B110]\]
                                                                                                                                                                                                                                                                                                                                       (*N =*4373)                                                                                                      (*N =*4345)                                                                   Secondary outcomes: survival to ED admission, hospital admission and hospital discharge, adverse events                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Adenosine antagonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Aminophylline in bradyasystolic cardiac arrest: a randomized placebo-controlled trial                                                                                        Randomized, placebo-controlled, double-blind, multicenter study of asystole and PEA arrest unresponsive to epinephrine and atropine                     Aminophylline 250 mg\                                                                                            Placebo\                                                                      Primary outcome: ROSC\                                                                                                                                                                                                                                                                                           No difference in ROSC. More tachyarrhythmias in the treatment group. Survival to hospital admission and survival to discharge were not different                                                                                                                                                                                                                                                                                                        Abu-Laban et al., Lancet 2006 \[[@B111]\]
                                                                                                                                                                                                                                                                                                                                       (*N =*486)                                                                                                       (*N =*485)                                                                    Secondary outcomes: duration of ROSC, survival to admission, survival to discharge, length of stay, 24-hour tachyarrhythmias, 24-hour seizures, 1-year neurologic outcome by GCS, Glasgow-Pittsburgh cerebral and overall performance scales, modified mini-mental state exam, functional status questionnaire                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Fluid management                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Capillary leakage in postcardiac arrest survivors during therapeutic hypothermia: a prospective, randomized study                                                            Randomized, controlled study                                                                                                                            7.2% hypertonic saline with 6% poly starch solution × 24 hours\                                                  Standard Fluid (Ringer\'s acetate) × 24 hours\                                Primary outcome: amount of fluid administered in 24 hours\                                                                                                                                                                                                                                                       The treatment group required significantly less fluid than the control group. There was no difference in MRI brain edema                                                                                                                                                                                                                                                                                                                                Heradstveit et al., Scand J Trauma Resusc Emerg Med 2010 \[[@B112]\]
                                                                                                                                                                                                                                                                                                                                       (*N =*10)                                                                                                        (*N =*9)                                                                      Secondary outcome: MRI vasogenic edema                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Barbiturate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Randomized clinical study of thiopental loading in comatose survivors of cardiac arrest                                                                                      Randomized, controlled, multicenter study                                                                                                               Thiopental 30 mg/kg IV load\                                                                                     Standard therapy (*N =*131)                                                   Primary outcome: Pittsburgh cerebral Performance scale at 6 and 12 months\                                                                                                                                                                                                                                       No difference in neurological outcome or mortality between groups                                                                                                                                                                                                                                                                                                                                                                                       Brain Resuscitation Clinical Trial I Study Group.\
                                                                                                                                                                                                                                                                                                                                       (*N =*131)                                                                                                                                                                                     Secondary outcomes: best neurological performance ever obtained during followup, time to recovery                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        NEJM 1986 \[[@B113]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Calcium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Calcium chloride: reassessment of use in asystole                                                                                                                            Randomized, double-blind, placebo-controlled study in prehospital asystolic cardiac arrest refractory to epinephrine, bicarbonate, and atropine         Calcium chloride\                                                                                                Placebo\                                                                      Primary outcome: ROSC\                                                                                                                                                                                                                                                                                           No difference in ROSC                                                                                                                                                                                                                                                                                                                                                                                                                                   Stueven et al.,\
                                                                                                                                                                                                                                                                                                                                       (*N =*18)                                                                                                        (*N =*14)                                                                     Secondary outcome: hospital discharge                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Ann Emerg Med 1984 \[[@B114]\]

  The effectiveness of calcium chloride in refractory electromechanical dissociation                                                                                           Randomized, blinded, placebo-controlled study of prehospital PEA arrest refractory to epinephrine and bicarbonate                                       Calcium chloride\                                                                                                Placebo\                                                                      Primary outcome: ROSC\                                                                                                                                                                                                                                                                                           No difference in ROSC but subgroup of patients with widened QRS did have more ROSC in calcium group (*P =*0.028)                                                                                                                                                                                                                                                                                                                                        Stueven et al.,\
                                                                                                                                                                                                                                                                                                                                       (*N =*48)                                                                                                        (*N =*42)                                                                     Secondary outcomes: survival to hospital discharge                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Ann Emerg Med\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               1985 \[[@B115]\]

  Lack of effectiveness of\                                                                                                                                                    Randomized, blinded, placebo controlled\                                                                                                                Calcium chloride\                                                                                                Placebo\                                                                      Primary outcome:\                                                                                                                                                                                                                                                                                                No difference in ROSC or hospital discharge                                                                                                                                                                                                                                                                                                                                                                                                             Stueven et al.,\
  calcium chloride in refractory asystole                                                                                                                                      study of prehospital asystolic cardiac arrest refractory to epinephrine, bicarbonate, and atropine                                                      (*N =*39)                                                                                                        (*N =*34)                                                                     ROSC\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Ann Emerg Med 1985 \[[@B116]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Secondary outcomes: survival to hospital discharge                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Sodium bicarbonate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Buffer therapy during out-of-hospital cardiopulmonary resuscitation                                                                                                          Randomized, double-blind, placebo-controlled study of out-of-hospital asystole or ventricular fibrillation refractory to first defibrillation attempt   Sodium bicarbonate 250 mL IV × 1\                                                                                Placebo\                                                                      Primary outcome: survival to ICU admission, survival to hospital discharge                                                                                                                                                                                                                                       No difference in survival to ICU admission or hospital discharge                                                                                                                                                                                                                                                                                                                                                                                        Dybvik et al.,\
                                                                                                                                                                                                                                                                                                                                       (*N =*245)                                                                                                       (*N =*257)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Resuscitation 1995 \[[@B117]\]

  Sodium bicarbonate improves outcome in prolonged prehospital cardiac arrest                                                                                                  Randomized, double-blind, placebo-controlled trial of prehospital cardiac arrest                                                                        Sodium bicarbonate (1 meq/kg) IV × 1\                                                                            Placebo\                                                                      Primary outcome: survival to ED\                                                                                                                                                                                                                                                                                 No difference in survival to ED admission or ROSC. Better survival with bicarbonate in the prolonged (\>15 minute) arrest group (*P =*0.007)                                                                                                                                                                                                                                                                                                            Vukmir and Katz,Am J Emerg Med\
                                                                                                                                                                                                                                                                                                                                       (*N =*175)                                                                                                       (*N =*155)                                                                    Secondary outcomes: ROSC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 2006 \[[@B118]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Hemofiltration                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  High-volume hemofiltration after out-of-hospital cardiac arrest: a randomized study                                                                                          Randomized, controlled trial of out-of-hospital ventricular fibrillation or asystole cardiac arrest                                                     Tier 1: hemofiltration (200 mL/kg/h) over 8 hours\                                                               Standard care\                                                                Primary outcome: survival at 6 months\                                                                                                                                                                                                                                                                           Significantly better survival compared to control in hemofiltration group (*P =*0.026) and hemofiltration plus hypothermia group (*P =*0.018). No difference in 6-month neurologic outcome                                                                                                                                                                                                                                                              Laurent et al.,\
                                                                                                                                                                                                                                                                                                                                       (*N =*20)\                                                                                                       (*N =*19)                                                                     Secondary outcome: intractable shock, Pittsburgh cerebral performance scale                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              J Am Coll Cardiol 2005 \[[@B39]\]
                                                                                                                                                                                                                                                                                                                                       Tier 2: hemofiltration plus hypothermia to 32°C × 24 hours\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                       (*N =*22)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Rhythm analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Early versus later rhythm analysis in patients with out-of-hospital cardiac arrest                                                                                           Cluster randomized, controlled, multicenter study of out-of-hospital cardiac arrest                                                                     Early rhythm analysis: 30--60 seconds of EMS CPR followed by ECG analysis\                                       Later rhythm analysis: 180 seconds of EMS CPR followed by ECG analysis\       Primary outcome: survival to hospital discharge with mRS 0--3\                                                                                                                                                                                                                                                   No difference in outcome between a brief and longer period of CPR before ECG analysis of rhythm                                                                                                                                                                                                                                                                                                                                                         Stiell et al.,\
                                                                                                                                                                                                                                                                                                                                       (*N =*5290)                                                                                                      (*N =*4643)                                                                   Secondary outcomes: survival to discharge, survival to hospital admission, ROSC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          NEJM 2011 \[[@B119]\]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Randomized controlled trials assessing neurologic outcomes after aneurysmal Subarachnoid hemorrhage---ongoing trials.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Trial name                                                                                                                                                                                                     Study design                                                                                                                        Treatment group                                                  Control group                                                                  Target enrollment   Outcome measure                                                                                                                                                                                                                                                                                   PI                                             Comments
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------------ ------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Statins                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Statins and cerebral blood flow in SAH                                                                                                                                                                         Randomized, double-blind efficacy study                                                                                             Simvastatin 80 mg/d for 21 days                                  Placebo                                                                        60                  Primary outcome: resting CBF and autoregulation 7--10 days after SAH\                                                                                                                                                                                                                             Michael Diringer,\                             Uses PET to understand the mechanism of statin use in vasospasm
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Secondary outcomes: OEF and CMRO~2~ 7--10 days after SAH                                                                                                                                                                                                                                          NCT00795288                                    

  The role of statins in preventing cerebral vasospasm secondary to subarachnoid hemorrhage                                                                                                                      Randomized, double-blind, parallel assignment                                                                                       Simvastatin 80 mg PO qd × 21 days                                Placebo                                                                        80                  Primary outcome: 6-month clinical outcome                                                                                                                                                                                                                                                         Eberval Figueiredo,\                           ---
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           NCT01346748                                    

  Use of simvastatin for the prevention of vasospasm in aneurysmal subarachnoid hemorrhage                                                                                                                       Randomized, double-blind, parallel assignment efficacy trial                                                                        Tier 1: Simvastatin 40 mg × 21 d or\                             Placebo                                                                        150                 Primary outcome:\                                                                                                                                                                                                                                                                                 Ben Roitberg,\                                 ---
                                                                                                                                                                                                                                                                                                                                                     Tier 2:\                                                                                                                                                            21-day GOS, mRS, and Barthel Index\                                                                                                                                                                                                                                                               NCT00487461                                    
                                                                                                                                                                                                                                                                                                                                                     Simvastatin 80 mg × 21 d                                                                                                                                            Secondary outcome: clinical vasospasm                                                                                                                                                                                                                                                                                                            

  High-dose simvastatin for aneurysmal subarachnoid hemorrhage (HDS-SAH)                                                                                                                                         Randomized, parallel assignment, double-blind efficacy study                                                                        Simvastatin 80 mg PO × 21 days                                   Simvastatin 40 mg PO × 21 days                                                 240                 Primary outcome:\                                                                                                                                                                                                                                                                                 George Wong, NCT01077206                       There may be a biochemical and neuroprotective dose-related relationship between simvastatin and delayed ischemic neurological deficits.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         delayed ischemic neurological deficit\                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Secondary Outcomes:\                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         LFTs, rhabdomyolysis, 3-month mRS, cost effectiveness                                                                                                                                                                                                                                                                                            

  Simvastatin in aneurysmal subarachnoid hemorrhage (STASH):\                                                                                                                                                    Randomized, placebo-controlled, double-blind phase III trial                                                                        Simvastatin 40 mg PO qd × 21 days                                Placebo                                                                        1600                Primary outcome: 6-month mRS\                                                                                                                                                                                                                                                                     Peter Kirkpatrick,\                            Simvastatin may improve CBF and inflammation following SAH
  a multicentre randomised controlled clinical trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Secondary outcome: need and intensity of delayed ischemic deficit rescue therapy, incidence and duration of delayed ischemic deficits, incidence and severity of sepsis, length of stay, discharge disposition                                                                                    NCT00731627                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Aneurysm repair                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  International subarachnoid aneurysm trial II comparing clinical outcomes of Surgical clipping and endovascular coiling for ruptured intracranial aneurysms not included in the original ISAT study (ISAT II)   Randomized, open label, safety/efficacy study of WFNS I--IV                                                                         Surgical Clipping                                                Endovascular Coiling                                                           1724                Primary outcome: 12-month mRS \> 2\                                                                                                                                                                                                                                                               Tim Darsaut, Max Findlay, and Jean Raymond,\   ISAT included primarily small anterior circulation aneurysms. The optimal treatment of other locations and sizes of aneurysms remains unclear and coiling may not be as durable as clipping
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Secondary outcomes: ICH following treatment, failure of aneurysm occlusion, all cause morbidity and mortality, aneurysm recurrence, hospitalization \> 20 days or discharge other than home, aneurysm rebleed                                                                                     NCT01668563                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Lipid peroxidation inhibitor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Acetaminophen in aSAH to inhibit lipid peroxidation and cerebral vasospasm                                                                                                                                     Randomized, double-blind, placebo-controlled, safety/efficacy trial                                                                 Group1: Acetaminophen 1 g q 6\                                   Placebo                                                                        120                 Primary outcome: F2-IsoP biomarkers for lipid peroxidation.\                                                                                                                                                                                                                                      John Oates,\                                   Hemoglobin released from lysed RBCs oxidizes and generates protein radicals that induce lipid peroxidation. Metabolites of peroxidations (F2-isoprostanes) are potent vasoconstrictors. Acetaminophen can inhibit these metabolites and NAC can inhibit lipid peroxidation
                                                                                                                                                                                                                                                                                                                                                     Group 2:\                                                                                                                                                           Secondary outcome: vasospasm and brain ischemia as assessed by CTA/CTP or MRI DWI                                                                                                                                                                                                                 NCT00585559                                    
                                                                                                                                                                                                                                                                                                                                                     NAC IV 0.5 g/h\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                     Group 3:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                     Acetaminophen 1 g q6 + NAC 0.5 g/h\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                     Group 4:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                     Acetaminophen 1.5 g q 6 + NAC 0.5 g/h                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Neuroprotective drugs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Effects of tiopronin on 3-aminopropanal level and neurologic outcome after aneurysmal SAH                                                                                                                      Randomized, double-blind, phase 2\                                                                                                  Tiopronin                                                        Placebo                                                                        60                  Primary outcome: serum and CSF 3AP levels\                                                                                                                                                                                                                                                        E Sander Connolly,\                            3AP is toxic metabolite produced during cerebral ischemia. It is neutralized by tiopronin
                                                                                                                                                                                                                 bioavailability                                                                                                                                                                                                                                                                                         Secondary outcomes:\                                                                                                                                                                                                                                                                              NCT01095731                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         12 month mRS, Barthel, Lawton, NIHSS, TICS\                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         adverse events                                                                                                                                                                                                                                                                                                                                   

  Lycopene following aneurysmal subarachnoid haemorrhage (LASH)                                                                                                                                                  Randomized, double-blind, placebo-controlled, efficacy study                                                                        Lycopene 30 mg PO qd × 21 days                                   Placebo                                                                        124                 Primary outcome: TCD vasospasm, duration of impaired autoregulation measured by TCD\                                                                                                                                                                                                              Karol Budohoski,\                              Lycopene is a natural antioxidant that may reduce vascular injury and inflammation and limit vasospasm
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Secondary Outcomes: LDL, oxy-LDL, CRP, circulating endothelial cells, endothelial progenitor cells                                                                                                                                                                                                NCT00905931                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Thrombolytics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Intraventricular tPA in the management of aneurysmal subarachnoid hemorrhage                                                                                                                                   Randomized, placebo-controlled, double-blind safety trail                                                                           tPA intraventricular q 12 h × 5 doses                            Placebo administered q 12 h × 5 doses                                          12                  Primary outcome: HCT rate and variance of ventricular and cisternal clot clearance\                                                                                                                                                                                                               Andreas Kramer,\                               Intraventricular TPA may accelerate clearance of IVH ameliorating vasospasm, hydrocephalus, and ICP
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Secondary outcome: hemorrhagic complications, ventriculostomy-related infections, TCD vasospasm, CT angio vasospasm, symptomatic vasospasm, CSF cytokines and coagulation measurements, ICP, fever burden, volume of CSF drainage, 6-month GOSE and EuroQOL                                       NCT01098890                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Transfusion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Effect of red blood cell transfusion on brain metabolism in patients with SAH                                                                                                                                  Open label safety/efficacy study in SAH patients with Hgb \< 12.5 g/dL and DCI, high risk for vasospasm or angiographic vasospasm   Transfusion of 1 unit of packed RBC over 1 hour                  NA                                                                             48                  Primary outcome: percent of brain regions with low oxygen delivery before and 1 hour after transfusion\                                                                                                                                                                                           Michael Diringer, NCT00968227                  Uses PET to assess the relationship between Hct and oxygen delivery in SAH patients
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Secondary outcomes: relationship of oxygen delivery and angiographic vasospasm                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Vasodilators                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Sildenafil for prevention of cerebral vasospasm (SIPCEVA)                                                                                                                                                      Randomized, double-blind, placebo-controlled, safety and efficacy study                                                             Tier 1: sildenafil 25 mg PO TID day 3--14 after SAH\             Placebo                                                                        18                  Primary outcome: New neurological deficit due to vasospasm up to 14 days after SAH\                                                                                                                                                                                                               Andre Cerutti Franciscatto,\                   ---
                                                                                                                                                                                                                                                                                                                                                     Tier 2:\                                                                                                                                                            Secondary outcomes: TCD spasm, mortality, adverse drug effects, length of stay, discharge mRS                                                                                                                                                                                                     NCT01091870                                    
                                                                                                                                                                                                                                                                                                                                                     sildenafil 50 mg PO TID day 3--14 after SAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Safety study of dantrolene in SAH                                                                                                                                                                              Randomized, double-blind safety study                                                                                               Dantrolene                                                       Placebo                                                                        30                  Primary outcome: tolerability, hyponatremia\                                                                                                                                                                                                                                                      Susanne Muehlschlegel,\                        Dantrolene is a muscle relaxant that may ameliorate vascular muscle tone and limit vasospasm
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Secondary outcomes: liver toxicity, hemodynamics, ICP, TCD, angiographic vasospasm treatments, 90-day GOS, mRS, and Barthel                                                                                                                                                                       NCT01024972                                    

  Safety and pharmacokinetic evaluation of nitrite for prevention of cerebral vasospasm                                                                                                                          Randomized, single-blind, parallel assignment safety study                                                                          Tier 1:\                                                         Placebo vehicle                                                                18                  Primary outcome: pharmacokinetics of 14-day sodium nitrite infusion\                                                                                                                                                                                                                              Edward Oldfield,\                              ---
                                                                                                                                                                                                                                                                                                                                                     sodium nitrite 32 nmol/kg/min\                                                                                                                                      Secondary outcomes: safety and efficacy                                                                                                                                                                                                                                                           NCT00873015                                    
                                                                                                                                                                                                                                                                                                                                                     Tier 2:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                     sodium nitrite 48 nmol/kg/min\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                     Tier 3:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                     sodium nitrite 64 nmol/kg/min                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Effects of prostacyclin infusion on cerebral vessels and metabolism in patients with subarachnoid hemorrhage                                                                                                   Randomized, placebo controlled, double-blind, parallel assignment, pharmacodynamics study                                           Tier 1:\                                                         Placebo, IV infusion day 5--10 after SAH                                       90                  Primary outcome: vasospasm measured by CT perfusion\                                                                                                                                                                                                                                              Rune Rasmussen, NCT01447095                    Prostacyclin may cause vasodilation and ameliorate vasospasm
                                                                                                                                                                                                                                                                                                                                                     prostacyclin 1 ng/kg/min day 5--10 after SAH\                                                                                                                       Secondary outcomes: cerebral metabolism measured by microdialysis, 3-month GOS, clinical vasospasm, brain tissue oxygen, CT angio vasospasm, MAP, serum S100b                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                     Tier 2:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                     prostacyclin 2 ng/kg/min day 5--10 after SAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Hypertensive, hypervolemic therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Induced hypertension for treatment of delayed cerebral ischemia after aneurysmal SAH\                                                                                                                          Randomized, Single blind safety/efficacy study of patients with SAH and DCI (clinically defined)                                    Induced hypertension with vasopressors and fluids for 48 hours   No induced hypertension                                                        240                 Primary outcome: mRS at 3 months\                                                                                                                                                                                                                                                                 Arjen Slooter and Walter van den Bergh,\       CBF measured in all patients using CTP at enrollment and 24--36 hours
  HIMALAIA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Secondary outcomes: proportion of treated patients who did not have clinical improvement of DCI symptoms within 24 hours, 30-day mortality, 3-month Barthel, SSQoL, hospital anxiety and depression scale, cognitive failures questionnaire, hospital complications, CTP results, medical costs   NCT01613235                                    

  Intensive management of pressure and volume expansion in patients with subarachnoid hemorrhage (IMPROVES)                                                                                                      Randomized, single-blind, factorial assignment                                                                                      Tier 1: hypervolemia + conventional blood pressure\              Normal volume, normal blood pressure                                           20                  Primary outcome: achievement of hemodynamic goals in each group                                                                                                                                                                                                                                   Miriam Treggiari,\                             Though triple H is a common therapy, its safety and efficacy have not been well quantified
                                                                                                                                                                                                                                                                                                                                                     Tier 2: normovolemia + hypertension\                                                                                                                                                                                                                                                                                                                                                                                                                                  NCT01414894                                    
                                                                                                                                                                                                                                                                                                                                                     Tier 3:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                     hypervolemia + hypertension                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  CSF diversion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  EARLYDRAIN: outcome after early lumbar CSF: drainage in aneurysmal subarachnoid hemorrhage                                                                                                                     Randomized, 2-arm controlled trial                                                                                                  Continuous lumbar CSF drainage of 120 mg qd × 7 d                Standard NICU care                                                             300                 Primary outcome: 6-month mRS\                                                                                                                                                                                                                                                                     Bardutzky J,\                                  Lumbar drainage to remove blood from the basal cisterns may limit delayed cerebral ischemia
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Secondary outcomes: 6-month mortality, angiographic vasospasm, TCD vasospasm, shunt insertion rate at 6 months                                                                                                                                                                                    NCT01258257                                    

  Cerebrospinal fluid (CSF) drainage study                                                                                                                                                                       Randomized, open label, parallel assignment study of SAH patients requiring external ventricular drainage (EVD)                     High volume CSF diversion (EVD at 5 mmHg) × 10 days              Conventional CSF diversion (EVD at 15 mm Hg), weaned at physician discretion   20                  Primary outcome: 90-day mRS\                                                                                                                                                                                                                                                                      Giuseppe Lanzino,\                             More aggressive CSF drainage may improve brain microcirculation and perfusion and lead to better neurological outcomes
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Secondary Outcome: radiologic infarction, TCD or angiographic vasospasm, shunt placement, ventriculitis, discharge mRS, 90 day mini-mental status exam, length of stay                                                                                                                            NCT01420978                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Antiepileptics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Comparison of short duration levetiracetam to extended course for seizure prophylaxis after subarachnoid hemorrhage                                                                                            Randomized, prospective, open label, parallel assignment, phase III, safety/efficacy study                                          Levetiracetam 1000 mg BID × 3 days                               Levetiracetam 1000 mg BID × hospital stay                                      460                 Primary outcome: In hospital seizures\                                                                                                                                                                                                                                                            Rajat Dhar,\                                   Antiepileptics can have long-term cognitive side effects. A short course may be just as efficacious as prolonged use
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Secondary outcome: Incidence of seizure after hospital discharge, adverse drug reactions, length of stay, cognitive and functional outcomes                                                                                                                                                       NCT01137110                                    

  Antiepileptic drugs and vascular risk markers                                                                                                                                                                  Randomized, open label, parallel assignment study                                                                                   Tier 1: phenytoin 5 mg/kg/d divided in 2 doses\                  No drug intervention                                                           200                 Primary outcome: serum cholesterol, non-HDL cholesterol, HDL, lipoprotein a, CRP\                                                                                                                                                                                                                 Prema Kishna and Scott Mintzer,\               Certain seizure medications may raise cholesterol levels and increase the risk of heart attack and stroke
                                                                                                                                                                                                                                                                                                                                                     Tier 2: valproate 15 mg/kg/d divided in 3 doses\                                                                                                                    Secondary outcome: acute seizures, late seizures, mRS at 8 and 16 weeks                                                                                                                                                                                                                           NCT00774306                                    
                                                                                                                                                                                                                                                                                                                                                     Tier 3: levetiracetam 1000-1500 mg/d divided in 2 doses                                                                                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Sedation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Effects of dexmedetomidine on inflammatory cytokines in patients with aneurysmal subarachnoid hemorrhage                                                                                                       Randomized, open label, parallel assignment efficacy study                                                                          Dexmedetomidine 0.2--1.5 mcg/kg/h                                Propofol 5--80 mcg/kg/min                                                      10                  Primary outcome: serum and CSF cytokines over 48 hours\                                                                                                                                                                                                                                           Shaun Keegan and Brittany Woolf,\              Dexmedetomidine may cause less inflammation over time than propofol
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Secondary outcomes: sedative and analgesic requirements, RASS and CAM-ICU scores, length of stay, delayed cerebral ischemia, GOSE at discharge                                                                                                                                                    NCT01565590                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Rehabilitation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Rehabilitation of patients after subarachnoid hemorrhage                                                                                                                                                       Nonrandomized, open label, parallel assignment                                                                                      Early multidisciplinary rehab and mobilization                   No intervention                                                                160                 Primary outcome: 10-week GOS\                                                                                                                                                                                                                                                                     Tanja Karic and Angelika Sorteberg,\           Early rehab may reduce complications and improve physical and cognitive function after SAH
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Secondary outcome: 3--6 month and 12-month GOSE, functional independence measure, coma recovery scale, disability rating scale, High-level Mobility Assessment tool, pain score                                                                                                                   NCT01656317                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Blood pressure control                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Safety and Efficacy Study of Clevidipine to Control Hypertension in Patients Admitted with Aneurysmal Subarachnoid Hemorrhage (CLASH)                                                                          Open label, safety, efficacy study, single group assignment (Phase 2)                                                               Clevidipine IV 2--32 mg/h for 24--48 hours                       NA                                                                             20                  Primary: Blood pressure within target range                                                                                                                                                                                                                                                       Panayiotis Varelas,\                           To assess how rapidly and safely Clevidipine can be used to control blood pressure in SAH patients.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           NCT00978822                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Other                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Cervical spinal cord stimulation for the prevention of cerebral vasospasm                                                                                                                                      Nonrandomized, open label                                                                                                           Spinal cord stimulation using MTS Trial System 3510              NA                                                                             12                  Primary outcome: cerebral vasospasm\                                                                                                                                                                                                                                                              Konstantin Slavin, NCT00766844                 ---
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Secondary outcome: adverse events                                                                                                                                                                                                                                                                                                                
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  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Trial name                                                                                                                                                                                                                                       Study\                                                                                                                                             Treatment\                                                                                                                          Control group                                            Target enrollment   Outcome measure                                                                                                                                                                                                                                                      PI                                                   Comments
                                                                                                                                                                                                                                                   design                                                                                                                                             group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------- ------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Neuroprotective drugs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Selenium to Improve Neurological Outcome after Cardiac Arrest (SCPR)                                                                                                                                                                             Randomized, double-blind, placebo-controlled, single-center, phase 2a efficacy study                                                               Sodium-selenite infusion × 7 days                                                                                                   Placebo                                                  52                  Primary outcome: neuron-specific enolase\                                                                                                                                                                                                                            Vanessa Stadlbauer and Karlheinz Smolle,\            Selenium can reduce oxidative stress after cardiac arrest and reduce inflammation
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Secondary outcomes: inflammation and oxidative stress markers, NIHSS and Glasgow Pittsburgh performance score at 6 months, selenium blood levels, glutathione peroxidase plasma levels                                                                               NCT01390506                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Magnesium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Clinical Study of the LRS ThermoSuit System in Post Arrest Patients with Intravenous Infusion of Magnesium Sulfate                                                                                                                               Randomized, double-blind, parallel assignment, safety/efficacy study of any rhythm                                                                 Thermosuit to target 34°C plus magnesium sulfate IV (30 mg/kg over 15 minutes)                                                      ThermoSuit to target 34°C plus placebo (normal saline)   14                  Primary outcome: cooling rate\                                                                                                                                                                                                                                       Michael Holzer and Andreas Janata, NCT00593164       Tests new device to achieve therapeutic hypothermia and the impact of magnesium on cooling performance and hemodynamics
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Secondary outcomes: time to target temperature, percentage of time in target temperature range, shivering, length of stay, neurologic status at discharge and 6 months, adverse events, survival at 24 hours, discharge and 30 days                                                                                       

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Hypothermia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Target Temperature Management after Cardiac Arrest (TTM)                                                                                                                                                                                         Randomized, double-blind, parallel assignment, multicenter, safety/efficacy trial for out-of-hospital cardiac arrest                               Target temperature 36°C × 24 h                                                                                                      Target temperature 33°C × 24 h                           850                 Primary outcome: All cause mortality\                                                                                                                                                                                                                                Niklas Nielsen and Hans, Friberg NCT01020916         Attempts to identify optimal hypothermia target temperature
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Secondary outcomes: 6-month composite all cause mortality and poor neurological outcome by cerebral performance scale, bleeding, 6-month neurological status and quality of life, mRS, Cerebral performance scale, mini-mental test, IQCODE, SF-36, adverse events                                                        

  Hypothermia After in-Hospital Cardiac Arrest (HACAinhospital)                                                                                                                                                                                    Randomized, single-blind, parallel assignment, single-center, safety/efficacy study for in-hospital arrests of any rhythm                          Mild therapeutic hypothermia 32--34°C × 24 hours.                                                                                   Standard care, no hypothermia                            440                 Primary outcome: all cause mortality at 6 months\                                                                                                                                                                                                                    Sebastian Wolfrum and Volkhard Kurowski,\            Tests whether hypothermia treatment will improve outcome after in-hospital arrest of any rhythm
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Secondary outcomes: 6 month Glasgow-Pittsburgh cerebral performance scale, in-hospital all-cause mortality                                                                                                                                                           NCT00457431                                          

  Intra-arrest Therapeutic Hypothermia in Prehospital Cardiac Arrest (HITUPPAC-BIO)                                                                                                                                                                Randomized, open label, parallel assignment, efficacy trial                                                                                        Hypothermia induction prehospital                                                                                                   Hypothermia induction at hospital arrival                250                 Primary outcomes: brain injury biomarkers at 72 h\                                                                                                                                                                                                                   Guillaume Debaty Jean Francois Timsit, NCT00886184   Assess utility of early hypothermia prehospital
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Secondary outcomes: ROSC, survival 72 h, GCS at 48 hours, cerebral performance scale at 28 days                                                                                                                                                                                                                           

  Induction of Mild Hypothermia Following Out-of-hospital Cardiac Arrest                                                                                                                                                                           Randomized, open label, single group assignment, efficacy study of any rhythm out of hospital arrest                                               Rapid infusion of 2 L of 4°C normal saline prior to ED arrival                                                                      Standard therapy                                         1364                Primary outcome: awake and command following at hospital discharge\                                                                                                                                                                                                  Francis Kim,\                                        Tests whether rapid induction of hypothermia with cold saline infusion is efficacious
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Secondary outcomes: days to awakening, days to death, 3 month neurological outcome                                                                                                                                                                                   NCT00391469                                          

  Comparing Therapeutic Hypothermia Using External and Internal Cooling for Post-Cardiac Arrest Patients                                                                                                                                           Randomized, open label, parallel assignment, efficacy trial                                                                                        External device (Arctic Sun) induced hypothermia                                                                                    Internal device (Alsius) induced hypothermia             51                  Primary outcome: Survival to hospital discharge\                                                                                                                                                                                                                     Marcus Ong, NCT00827957                              Identifying the most efficient method of cooling may improve outcome after cardiac arrest
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Secondary outcome: 1 year neurological status                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Hypothermia + ECMO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Refractory Out-of-Hospital Cardiac Arrest Treated with Mechanical CPR, Hypothermia, ECMO and Early Reperfusion (CHEER)                                                                                                                           Nonrandomized, single group, open label, safety/efficacy trail for patients who fail standard resuscitation                                        Automated CPR, ECMO, coronary angiography, therapeutic hypothermia                                                                  NA                                                       24                  Primary outcome: survival to hospital discharge\                                                                                                                                                                                                                     Stephen Bernard and Dion Stub, NCT01186614           Aggressive resuscitation may improve outcome in patients who fail standard resuscitation
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Secondary outcomes: cerebral performance Scale, time to ECMO insertion, neurologic biomarkers, cardiac recovery                                                                                                                                                                                                           

  Hyperinvasive approach to out-of-hospital cardiac arrest using mechanical chest compression device, prehospital intraarrest cooling, extracorporeal Life support and early Invasive assessment compared to standard of care: Prague OHCA Study   Randomized, open-label, parallel group, safety/efficacy study                                                                                      Prehospital mechanical compression device, intraarrest cooling and in hospital ECLS (compression device, Rhinochill, PLS ECMO)      Standard care                                            170                 Primary outcome: composite endpoint of survival with good neurological outcome (cerebral performance scale)\                                                                                                                                                         Jan Belohlavek and Ondrej Smid,\                     Aggressive, early intervention may improve cerebral outcomes
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Secondary outcome: 30 day cerebral performance scale, 30 day cardiac recovery                                                                                                                                                                                        NCT01511666                                          

  Emergency Preservation and Resuscitation (EPR) for Cardiac Arrest from Trauma (EPR-CAT)                                                                                                                                                          Nonrandomized, open label, parallel assignment, safety/efficacy study                                                                              Profound hypothermia \< 10°C with cold saline infusion into aorta followed by resuscitation/rewarming with cardiopulmonary bypass   Standard treatment                                       20                  Primary outcome: survival to hospital discharge without major disability by GOSE\                                                                                                                                                                                    Samuel Tisherman,\                                   Resuscitation technique for trauma patients that have arrested from exsanguination
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Secondary outcomes: achieving target temperature in 1 hour, 28 day survival, 6 month neurological function, multiple organ system dysfunction                                                                                                                        NCT01042015                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  HypotherMia + xenon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Effect of xenon and therapeutic hypothemia on brain and on neuroloigcal outcome following brain ischemia in cardiac arrest patients (Xe-hypotheca)                                                                                               Randomzied, open label, parallel assignment, phase 2 safety/efficacy trial for ventricular fibrillation and nonperfusing ventricular tachycardia   Hypothermia 33°C × 24 h and Xenon inhalation × 24 hours target end tidal 40%                                                        Hypothermia 33°C × 24 h                                  110                 Primary outcome: PET and MRI ischemia at 24 hours and 10 days\                                                                                                                                                                                                       Timo Laitio,\                                        Xenon may be synergistically neuroprotective in combination with hypothermia post arrest by limiting cerebral hypoxia, neuronal loss, and mitochondrial dysfunction
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Secondary outcomes: neurological outcome at 6 months, TTE                                                                                                                                                                                                            NCT00879892                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Chest compresions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Continuous chest compressions                                                                                                                                                                                                                    Randomized, open label, multicenter, crossover assignment study of out-of-hospital cardiac arrest of any rhythm                                    Continuous chest compressions                                                                                                       Interrupted chest compressions with ventilation 30 : 2   23600               Primary outcome: survival to hospital discharge\                                                                                                                                                                                                                     Myron Weisfeldt,\                                    Continuous CPR without interruption for ventilation may be superior to interrupted compression with ventilation ratio of 30 : 2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Secondary outcomes: mRS at discharge, adverse events                                                                                                                                                                                                                 NCT01372748                                          

  LUCAS chest compressor versus manual chest compression in out-of-hospital sudden cardiac arrest: LUCAT trial                                                                                                                                     Randomized, open label, parallel assignment, efficacy study                                                                                        Mechanical continuous chest compressions performed by LUCAS device                                                                  Manual chest compressions                                400                 Primary outcome: survival to hospital admission, survival to discharge with good neurological state by cerebral performance Scale\                                                                                                                                   Francesc Carmona Jimenez, Rosa-Maria Lidon,\         Mechanical chest compression may be superior to manual chest compression
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Secondary outcomes: ROSC, end tidal CO~2~, SOFA scale, length of stay, metabolic and inflammatory markers, LV function                                                                                                                                               NCT01521208                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Cerebral oxygenation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Cerebral Oxygenation in Cardiac Arrest and Hypothermia                                                                                                                                                                                           Open label, safety and efficacy study                                                                                                              Near-infrared monitoring                                                                                                            Standard therapy, no monitoring                          70                  Primary outcome: survival to discharge\                                                                                                                                                                                                                              Christian Storm, NCT01531426                         Near-infrared spectroscopy (NIRS) could be a new-noninvasive marker for outcome after cardiac arrest. Low NIRS may correlate with poor outcome
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Secondary outcomes: cerebral performance scale at discharge and 12 months                                                                                                                                                                                                                                                 
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Number of randomized, controlled trials published and ongoing for aneurysmal subarachnoid hemorrhage and cardiac arrest.

  Intervention                                SAH       Cardiac arrest              
  ------------------------------------------- --------- ---------------- ---------- --------
  Calcium channel blockers                    10 (18)   0                4 (9)      0
  Antifibrinolytics                           5 (9)     0                0          0
  Neuroprotective drugs                       5 (9)     2 (8)            1 (2)      1 (7)
  Statins                                     4 (7)     5 (20)           0          0
  Aneurysm clip or coil                       4 (7)     1 (4)            NA         NA
  Lipid peroxidation inhibitor                4 (7)     1 (4)            0          0
  Thrombolytics                               3 (5)     1 (4)            2 (4)      0
  Antiplatelets                               3 (5)     0                0          0
  Steroids                                    3 (5)     0                1 (2)      0
  Transfusion/blood products/erythropoietin   3 (5)     1 (4)            0          0
  Vasodilators                                3 (5)     4 (16)           0          0
  Pressors or HHH                             2 (4)     2 (8)            9 (19.5)   0
  Magnesium                                   2 (4)     0                5 (11)     1 (7)
  Rho-kinase inhibitor (fasudil)              2 (4)     0                0          0
  Adrenergic blockade                         1 (2)     0                0          0
  Endovascular therapy                        1 (2)     0                NA         NA
  Insulin/glucose control                     1 (2)     0                2 (4)      0
  Hypothermia                                 1 (2)     0                5 (11)     9 (64)
  CSF diversion                               0         2 (8)            0          0
  Antiepileptics                              0         2 (8)            0          0
  Sedation                                    0         1 (4)            0          0
  Rehabilitation                              0         1 (4)            0          0
  Blood pressure                              0         1 (4)            0          0
  Other                                       0         1 (4)            0          0
  Chest compressions                          NA        NA               7 (15)     2 (14)
  Adenosine antagonist                        0         0                1 (2)      0
  Fluid management                            0         0                1 (2)      0
  Barbiturate                                 0         0                1 (2)      0
  Cerebral oxygenation                        0         0                0          1 (7)
  Calcium chloride                            0         0                3 (7)      0
  Sodium bicarbonate                          0         0                2 (4)      0
  Hemofiltration                              0         0                1 (2)      0
  Rhythm analysis                             0         0                1 (2)      0
                                                                                    
  Total                                       57        25               46         14

[^1]: Academic Editor: R. Loch Macdonald
